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ABBREVATIONS 
CSF  Cerebrospinal fluid 
MZN  Modified Zeihl-Neelsen 
TBM  Tuberculosis meningitis 
CNS  Central nervous system 
AFB  Acid fast bacilli 
HIV  Human immune deficiency virus 
ADA  Adenosine deaminase 
LDH  Lactate dehydrogenase 
Ig  Immunoglobulin 
TNF  Tumour necrosis factor 
IFN  Interferon  
IL  Interleukin 
MRC  Medical research centre 
PCR  Polymerase chain reaction 
ATT  Anti-tuberculous treatment 
LP  Lumbar puncture 
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INTRODUCTION  
Tuberculous meningitis is a serious manifestation of extra-pulmonary tuberculosis, 
associated with mortality and severe morbidity.  In India the estimated mortality due to 
tuberculous meningitis is 1.5 per 100,000 population(1). Among 1.61 million new and 
relapse cases of tuberculosis reported in India for the year 2014, 17% were new extra-
pulmonary tuberculosis(2). Poor outcome is very well associated with the delay in 
initiation of the treatment(3). Diagnostic test to diagnose early and microbiologically 
confirm M. tuberculosis, is crucial in prompt initiation of treatment in tuberculous 
meningitis(4).  
The CSF culture is gold standard for the confirmation of TBM. However, it has issues 
with the sensitivity which widely vary 25%-70%, and the turnaround time, which can 
vary from 2 to 8 weeks. Microscopy by either Zeihl-Neelsen or auramine rhodamine 
fluorescent staining procedures is employed in rapid confirmation of the disease.  
However, only one in four suspected TBM patient have a positive result by auramine 
staining in the CSF sample(5). Xpert TB/RIF PCR made a huge impact in the rapid 
diagnosis of pulmonary tuberculosis and ability to detect rifampicin resistance, however 
it does not perform well in CSF in diagnosis of TBM (poor sensitivity) and it is not 
validated. 
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Development of rapid diagnostic investigations to confirm diagnosis is a rapidly evolving 
research field. It involves search, from antigen detection to gene amplification; surrogate 
marker search like adenosine deaminase levels, interferon gamma response to challenged 
TB proteins and so on.  
Several case definitions were developed used for research as well for diagnosis to decide 
early initiation of the treatment. Thwaites et al developed a scoring system (Table 2) to 
differentiate tuberculous meningitis from bacterial meningitis. In 2010 Marais et al 
developed uniform diagnostic criteria for the diagnosis of TBM as there are limited 
diagnostic test available and to compare tuberculous meningitis research data. The 
diagnostic definition includes definite, probable, possible, and not tuberculous 
meningitis. 
In 2012 Chen et al described a promising newer rapid diagnostic tool for the diagnosis of 
tuberculous meningitis(6). This is a modified Zeihl-Neelsen staining technique for 
microscopy, which is based on the principle of staining the intracellular M. tuberculosis.  
In the present sudy, we plan to evaluate the diagnostic accuracy of a modified Zeihl-
Neelsen test for the diagnosis of TBM, using the consensus uniform research case 
definition criteria for diagnosis of TBM as the gold standard. 
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AIM AND OBJECTIVE 
1.1. AIM 
To improve the diagnostic accuracy of tuberculous meningitis 
1.2. OBJECTIVE 
To evaluate the diagnostic accuracy of the modified Zeihl-Neelsen test to confirm the 
diagnosis of TBM, the reference standard being the consensus uniform research case 
definition criteria for diagnosis of TBM. 
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REVIEW OF LITERATURE 
1.3. EPIDEMIOLOGY 
Tuberculous meningitis is a serious manifestation of extra-pulmonary tuberculosis, 
associated with mortality and severe morbidity(7,8). The global incidence of tuberculosis 
was 9.7 million in the year 2007, the prevalence was 13.7 million. Among 1.61 million 
new and relapse cases reported in India for the year 2014, 17% were new extra-
pulmonary tuberculosis(2). In a retrospective study from our institution evaluating 306 
patients with central nervous system infection, 84.6% (260/306) had a final diagnosis of 
tuberculous meningitis by the treating physician(9). 
In India the estimated mortality due to tuberculous meningitis is 1.5 per 100,000 
population(1). Risk factors to develop TBM are malnutrition, HIV, old and young age, 
cancer and young child with primary TB. There is increased risk of TBM among patient 
on anti tumour necrosis factor -alpha antibody. 
TBM has an initial prodrome phase of malaise, low grade fever, headache and vomiting 
which usually last for weeks, after which patients worsen with altered sensorium, 
seizures, stroke, hydrocephalus and cranial nerve palsies, sensorineural hearing loss, 
stroke syndromes, hydrocephalus, coma and seizures. 
18 
 
1.4. PATHOGENESIS 
CNS tuberculosis comprises of three different clinical entities:  tuberculoma, meningitis 
and spinal arachnoiditis. CNS tuberculosis is often fatal with high morbidity affecting the 
children and young adult. It is commonly seen in the part of the world where TB is 
endemic following post primary infection whereas in low prevalence area  
extrapulmonary TB is commonly seen in adults due to reactivation and most commonly 
presents as meningitis. (10–12) 
Much of the evidence for pathogenesis of CNS tuberculosis comes from necropsy 
findings in 1933(13). CNS meningitis occurs subsequent to rupture of subependymal 
tuberculomas formed around the Mycobacterium tuberculosis deposited following 
hematogenous spread. 
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Figure 1-Pathogenesis of TBM 
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M. tuberculosis primarily infects via lungs through inhalation of infectious airborne 
droplets following which the tubercle bacilli invades the macrophages through multitude 
of receptor interactions(14).  
 
Figure 2-Molecular mechanisms and immunopathogenesis. 
a, M. tuberculosis are depicted as small yellow bacilli, and exudative 
meningitis is shown in pink. b, Magnified view of a TBM lesion in the brain 
parenchyma demonstrating interaction between immune cells and bacteria. c, 
Details of the specialized barriers that separate the CNS from the systemic 
circulation are shown. CSF, cerebrospinal fluid; DAMPs, damage-associated 
molecular patterns; PAMPs, pathogen-associated molecular patterns; APC, 
antigen-presenting cell; PMNs, polymorphonuclear leukocytes. 
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Soon the innate cells are triggered releasing multiple cytokines activating type 1 helper 
cell mediated immune response containing the tubercle by forming granulomas. There 
happens a low level bacteremia before the actual containment by granuloma formation 
with a tendency to spread and seeding occurs in region of high oxygenation like 
brain(15). 
There is a physiological blood brain barrier formed by tightly apposed human brain 
microvascular endothelial cells supported by astrocyte processes interspersed with the 
extracellular matrix that separates the CNS from systemic circulation(15). Paracellular 
tight junctions and transcellular restriction to large hydrophilic molecules act as a barrier 
to circulating pathogens. In spite of all protective mechanisms, CNS is still vulnerable to 
lot of bacterial, viral, parasite and fungal infections. 
The seminal work by Arnold Rich and Howard McCordock on CNS tuberculosis by 
performing series of autopsies heralded the breakthrough in our understanding of the 
pathogenesis of CNS tuberculosis. During the initial bacteremia, mycobacterium bacilli 
gets deposited to form caseating foci also known as Rich foci. Later they rupture into 
subarachnoid space causing diffuse inflammatory meningitis in contrast to the direct 
hematogenous spread of other bacterial meningitis. But how mycobacterium was able to 
cross tightly knit blood brain barrier is yet to be elucidated. Theoretically they can cross 
as free-living organisms or infected macrophages or neutrophils. Historically, intravenous 
inoculation of M. tuberculosis or M. bovis  in guinea pigs/rabbits  caused  CNS 
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tuberculoma(16). Recently, Intravenous inoculation of Zebra fish with M. marinum 
caused CNS tuberculoma surrounding CNS blood vessels in almost 70% of cases. 
Infection with mutant M. marinum lacking TB virulence factor EsxA homologue gene 
caused altered pathology with high bacterial load due to preservation of penetrating 
ability but without much granuloma formation. Thus EsxA mediates the pathogenesis of 
CNS TB (17). 
Bacilli must replicate in the CNS to establish CNS pathogenesis. But only lower load of 
TB bacilli in CSF was observed and even it was very difficult to isolate viable bacilli 
from CSF. In experimental animal models, even inoculation of dead bacilli into meninges 
in TB sensitized animals caused severe tissue damage indicating dysregulated immune 
response the main cause for CNS TB pathogenesis(18) 
Experiments with macrophages infected tubercle bacilli caused activation of NLRP3 
(NACHT, LRR and PYD domains-containing protein 3) inflammasome - composed of 
NLRP3, apoptosis-associated speck-like protein and caspase(19) in cultured mouse 
microglial cells. 
Another study found low levels of glucose and high level of csf lactate were associated 
with death(20), thus corroborating other studies showing decreased CSF glucose and 
energy metabolites and increased CSF lactate in TBM(21). 
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In rabbit model of TBM, the TNF level correlates with the pathology and treatment with 
antibiotics and thalidomide protects from death(22). In another study, they had shown 
correlation between IL-1beta, TNF and post contrast cerebral cortical signal intensity(23). 
In a related study, IL-6, IL-10,IL-8,  IL-1beta were found to be elevated in TBM CSF and 
decreased after 3 months of therapy(23). But the levels of cytokines were not correlative 
to the clinical, radiological outcome of meningitis thus precluding their use to assess 
severity of the disease and prognosis. 
Dexamethasone treatment in culture markedly suppresses cytokine production by 
microglial and astrocyte cells (24). In clinical trials, dexamethasone reduces total CSF 
protein significantly but only marginally reduces TNF gamma and other cytokines were 
not reduced. Subsequent study showed increased CSF IL-6 concentration was 
independently associated with severe TBM but  not with death or disability(25,26) 
IFN gamma enhances immunity and survival in HIV 1 co-infected TBM as its lower CSF 
level were independently associated with death. Further studies have shown induction of 
inflammasomes and activation of innate cytokine response which led to phagocyte 
activation. However, interferon gamma secretion by acquired type 1 T helper cell is also 
documented. There is also a relationship between high interferon gamma levels and 
tuberculoma formation. Growth factors have also been identified as contributing agents in 
vascular pathology of TBM. Many studies favour the influence of immune response 
genes which are under polymorphic genetic influence thus, predisposing the individuals 
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to TBM. Polymorphism in innate immune response receptors or signaling pathways 
affect susceptibility of individual to TBM. TBM susceptibility also depends on lineage of 
Mycobacterium tuberculosis. Lineage 2 was more common in children with TBM in 
China than other lineages. Some studies showed lineages 2 and 4 showed increased 
propensity to cause TBM(25). 
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1.5. CLINICAL PRESENTATION 
 Immune response against M. tuberculosis influences the spectrum of the clinical features 
of TBM. Tuberculous meningitis often presents with a subacute febrile illness with 
headache and slight mental changes. There is usually a prodrome of weeks of low-grade 
fever, anorexia, malaise, myalgia, and irritability. (8). Without any therapy there is 
progressive dominance of the meningitic symptom, with fall in consciousness, cranial 
 
Figure 3-Clinical Presentation of TBM in 2 case series 
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nerve palsies mainly- third and fifth cranial nerve (50% of patients) and hemiplegia or 
paraplegia in 10% of patient. Further progression is characterized by coma, 
hydrocephalus and intracranial hypertension. Patient with advanced to HIV 1 co-infection 
are highly susceptible and often associated with extrapulmonary dissemination.  
Duration of the illness is one of the most important features that distinguishes a 
tuberculous meningitis from a pyogenic meningitis. The mean duration of illness seen in 
some of the studies are mentioned below (Figure 4). 
 
Figure 4-Mean Duration of illness-In Days 
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Choroid tubercles can be seen in the fundus examination, which can help in the diagnosis. 
In a study done among 52 patients, tubercles was seen in 18 patients (34.6%)(27).  
Choroid tubercles are seen in disseminated or military tuberculosis.  
Myoclonus and cerebellar dysfunction are also reported in few reports. 
Among patient with hyponatremia SIADH to be suspected, it is due to antidiuretic 
hormone secretion, it is found to have poor prognosis with TBM.  
The Medical Research Council (MRC) disease severity grade method helps to define 
TBM disease severity and predicts outcome. (Table 1). 
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 In HIV-1 negative people, the rate of death or severe neurological disability in MRC 
grades I, II, and III are approximately 15%, 30% and 50%, respectively. In people with 
HIV‑1 coinfection it raise to 25%, 50%, and 80%, respectively(28). 
In developing countries patients present with advanced disease, in a study done in 
Kashmir, 60% of the patient present with severe disease i.e. (MRC II and III). 
Table 1. The Medical Research Council tuberculous meningitis severity grade 
In 1948, Medical Research Council investigators in the UK graded tuberculous 
meningitis for the first trial of streptomycin as: 
Early  no clinical signs of meningitis or focal neurology and fully 
conscious 
Medium patient’s condition falls between early and advanced 
Advanced extremely ill, in a deep coma 
With the introduction of the Glasgow Coma Scale (GCS) in 1974, this 
classification was modified to: 
Grade I  (GCS score 15; no focal neurological signs) 
Grade II  (GCS score 11–14, or 15 with focal neurological signs) 
Grade III  (GCS score ≤10) 
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1.6. DIAGNOSIS 
Diagnosis of tuberculous is a challenging for the treating physician, as there is difficult in 
every level. The reason considered were a poorly understood pathogenesis, difficulty 
confirming the clinical suspicion due to lack of rapid, sensitive affordable diagnostic 
test(29).  
1.7. CHALLENGES IN RAPID DIAGNOSIS 
Though mycobacterial isolation from culture being the gold standard, to wait for the 
result to initiate treatment would be late; which varies with latest methodology from 2 
weeks, sometimes up to 8 weeks(30). The sensitivity of culture is also varies from 25% to 
70%(31). Most often diagnosis is usually made on clinical evidence, combined with other 
supportive laboratory, and radiological findings. Several case definitions were developed 
used for research as well for diagnosis to decide early initiation of the treatment. In 2010 
Marais et al developed uniform diagnostic criteria for classification of definite, probable, 
possible, and not tuberculous meningitis, in view of limited available diagnostic test and 
to compare the tuberculous meningitis data(29).  
Development of rapid diagnostic investigations to confirm diagnosis is a rapidly evolving 
research field. It involves search, from antigen detection to gene amplification; surrogate 
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marker search like adenosine deaminase levels, interferon gamma response to challenged 
TB proteins and so on. Some of the diagnostic test aiding in early diagnosing are, 
1. CLINICAL DIAGNOSIS 
Several case definitions were developed used for research as well for diagnosis to decide 
early initiation of the treatment. Two such definition is discussed below 
Diagnostic Scoring by Thwaites et al, Vietnam 
Uniform diagnostic criteria, Marais et al 2010. 
DIAGNOSTIC SCORING BY THWAITES: 
Thwaites et al developed a scoring system (Table 2) to differentiate tuberculous 
meningitis from bacterial meningitis. In the study, done in Vietnam they compared the 
laboratory features and clinical feature of 251 adults who admitted with diagnostic 
criteria for bacterial meningitis(n=108) or tuberculosis meningitis (n=143). Multivariate 
logistic regression analysis was done for various features that were predictive of TBM to 
form the diagnostic scoring system(32). 
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Table 2- Thwaites score 
 
 
A calculated score of (<= 4) has a sensitivity of 97% and 91 % specific for a diagnosis of 
TBM, a score > 4 for bacterial meningitis. Further on prospectively testing 42 adults with 
TBM and 33 adults with bacterial meningitis, the sensitivity was found to be 86% and 
specificity to be 79%.  
In  a retrospective study of 126 patient with meningitis, Thwaites score had a sensitivity 
of 95.6% and 70.8% against a reference published criteria(Table 3)(32,33). Among 
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microbiologically confirmed patients (59 bacterial meningitis and 12 TBM), Thwaites 
score had a sensitivity and specificity 91.7% and 79.7% respectively. 
Table 3- Diagnostic criteria for tuberculous and bacterial meningitis 
 
 
TBM UNIFORM CASE DEFINITION: 
In 2010 Marais et al developed uniform diagnostic criteria for the diagnosis of TBM as 
there are limited diagnostic test available and to compare tuberculous meningitis research 
data. The diagnostic definition includes definite, probable, possible, and not tuberculous 
meningitis. (Table 4)  
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For the diagnosis of probable and possible tuberculous meningitis, there is a scoring 
system (Table 5). The component includes, the symptoms and sign suggestive of 
tuberculous meningitis associated with clinical criteria, CSF criteria and imaging criteria. 
Table 4  TBM consensus uniform research case definition criteria 
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A score of 6-9 without imaging criteria and 6-11 with imaging criteria would be possible 
TBM. A score of >10 without imaging criteria and >12 with imaging criteria would be a 
probable TBM. 
In a study done in CMC Vellore, the authors compared the Thwaites and the consensus 
uniform research case definition criteria. Among 306 patient the with CNS infection, the 
Table 5- Consensus uniform research case definition criteria for TBM 
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treating physician diagnosis of TBM was 84.6% (260/306), the Thwaites score classified 
284(92.8%) as TBM and Lancet score classified 29 patients (9.5%) as definite-TBM, 
43patient (14.4%) as “probable TBM”, 186 cases (60.8%) as “possible TBM”. They 
found there was only moderate agreement between consensus uniform research case 
definition criteria and Thwaites scoring. 
  
36 
 
2. LAB DIAGNOSIS  
GENE AMPLIFICATION  
Xpert MTB/RIF assay, a gene amplification test with an added advantage of rifampicin 
resistance detection, is approved by United states food and drug administration for 
detection of M. tuberculosis in pulmonary tuberculosis(34). Nonetheless it has also been 
tried in extra pulmonary tuberculosis. In one of a recent meta-analysis including thirty-six 
studies, on diagnostic accuracy of Xpert MTB/RIF for the detection of extra-pulmonary 
tuberculosis (EPTB), they have found a sensitivity of 0.69 (0.54–0.81)  and specificity 
0.97 (0.95–0.98) in CSF sample for tuberculous meningitis(35). 
In a study by J S Michael et al 2002 in our institution evaluating polymerase chain 
reaction using IS 6110 antigen for rapid diagnosis of TBM, found an overall sensitivity of 
71% and a specificity of 97%, and a sensitivity of 77% in definite TBM group.(5)Xpert 
MTB/RIF is  limited by low its sensitivity; though a positive result can rapidly confirm 
the disease due to its high specificity, a negative report cannot rule out the disease due to 
low sensitivity(35). 
XPERT MTB/RIF ULTRA  
The Xpert MTB/RIF Ultra (Xpert Ultra) is a new, fully automated, nested real-time PCR 
assay for the GeneXpert. Nathan C Bahr et all evaluated the diagnostic accuracy of the 
test among 129 HIV infected patients. They found a sensitivity of 70% (95% CI 47-87; 
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16/23) for probable or definite tuberculous meningitis compared with 43% (23–66; 
10/23) for Xpert and 43% (23–66; 10/23) for culture. They also observed centrifuging 
larger volume of CSF >6ml had an increase diagnostic yield. For a culture proven TBM 
the sensitivity was found to be 95% (21/22) it was superior to either Xpert (45%; 10/ 22;) 
or culture (45%; 10/ 22)(36).  
 
AFB MICROSCOPY 
Microscopy by either Zeihl-Neelsen or fluorescent staining procedures is employed in 
rapid confirmation of the disease. However, one in four suspected TBM patient have a 
positive result by auramine staining in the CSF sample(5). In the Haydarpasa-1 study a 
largest case series data including 469 patients on the diagnosis of tuberculous meningitis 
(TBM), the sensitivity was found 27.3% for detection of M. tuberculosis by Zeihl-
Neelsen technique(37). Due to the better sensitivity auramine staining(florescent staining 
technique) replaced the traditional Zeihl-Neelsen staining(38). There has been observed 
high variation in the sensitivities of some of the older studies and recent studies, which 
may reflect the loss of the art of staining, quotes an review article(39). 
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INTERFERON GAMMA RELEASE ASSAY (IGRA) 
 Lymphocyte in the host release interferon gamma (INF-γ) on exposure to 
Mycobacterium tuberculosis; In vitro measuring the production of IFN-γ to the 
stimulation by Mycobacterial antigen is the principle of this assay.  
 
Figure 5-Interferon Gamma Release Assays 
Antigens specific for a given infecting agent (often in the form of purified 
protein derivatives) are applied to whole-blood samples from infected 
individuals, T cells sensitized to the antigens will be present in the blood, 
and will bind to the antigen. The T cells will then release Interferon-Gamma; 
the presence of sensitized T-cells in infected individuals will result in far 
higher levels of IFN-G release than among uninfected individuals. The 
presence of IFN-G can then be quantified using a single step enzyme-linked 
immunosorbent assay (ELISA) using anti-IFN-G antibodies(40). 
A recent meta-analysis on diagnostic accuracy of IGRAs in CSF and blood in the 
diagnosis of tuberculous meningitis, found a sensitivity of 0.77% (0.69–0.84) and a 
specificity of 0.88% (0.74–0.95) for CSF IGRA and a sensitivity of 0.78 (0.67–0.86) and 
a specificity of 0.61 (0.47–0.73) for blood IGRA.  They have concluded CSF IGRA has 
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moderate diagnostic value, and blood IGRA has limited diagnostic value in the diagnosis 
of TBM (41). 
Adenosine deaminase: Adenosine deaminase level in CSF, a surrogate marker has been 
evaluated for the diagnosis for the diagnosis of tuberculous meningitis. In a meta-analysis 
including 10 studies on the evaluation of adenosine deaminase levels in CSF as a 
diagnostic indicator for TBM, got a pooled sensitivity of 0.79 (95%CI 0.75–0.83); pooled 
estimate of speciﬁcity was 0.91 (95% CI 0.89–0.93). However the cut-off for defining a 
positive and negative result value is quite varying among the studies included in the 
meta-analysis, even with the same method of analysis(42). 
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3. IMAGING IN TUBERCULOUS MENINGITIS 
Imaging helps in the diagnosis, prognostication and evaluation of complication of 
TBM. 
CHEST X-RAY: 
Chest x ray evidence of co-existing pulmonary tuberculosis gives clues to the etiology of 
meningitis. Miliary mottling on the chest x ray is a feature of disseminated tuberculosis 
(refer- Figure 6). 
There is always some evidence of chest x ray finding of tuberculosis in pulmonary 
tuberculosis. In a study done in Delhi, among pulmonary tuberculosis and HIV negative 
patient 88% patient had some evidence of tuberculosis on chest X ray. 
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Figure 6-Miliary tuberculosis 
Chest radiography which revealed diffuse, bilateral, small lung nodules. 
 
Miliary tuberculosis is seen in 12% of patients with tuberculous meningitis. 
NEUROIMAGING: 
Both MRI and CT of the brain are useful in assessing the complication of TB meningitis. 
MRI is considered better over CT brain. Early disease might not show any changes. 
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Figure 7 Basal meningeal enhancement and Infarct. 
A. Shows contrast enhancement of the base of the brain. B. Infarct in the 
right basal ganglia and thalamus.(43) 
 
The classical findings described are leptomeningeal enhancement, basal cisternal 
enhancement, ventriculomegaly, infarcts, and tuberculomas. Interpreting of the images 
are subject to inter- observer variability. In a retrospective study evaluating the CT 
finding of 289 patients with TB meningitis, 254(88%) had some abnormal imaging 
features. Among them 204 patients had hydrocephalus, 62 patients had parenchymal 
enhancement, 49 patients had contrast enhancement of the basal cisterns, 39 patients had 
cerebral infarcts and cerebral tuberculomas were seen in 14 patients. 
                  
Figure 1 Basal meningeal enhancement and Infarct. 
A. Shows constrast enhancement of the base of the brain. B. Infarct in the 
right basal gangli  and thala us.(42) 
 
A
c 
B
c 
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Figure 8-MRI showing tuberculoma. 
A. Admission MRI. B. MRI after 9 months of antitubercular therapy. A and 
B: MRI brain axial images; at left, non-contrast T1-weighted image; middle, 
post-gadolinium T1-weighted image; and at right, T2-weighted fluid-
attenuated inversion recovery (FLAIR)(44). 
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 In a study evaluating CT imaging features contributing to the diagnosis of TBM, 
there was poor inter-rater variability on the consensus case definition imaging 
parameters.  A presence of infarct and tuberculomas helps in rule in the disease, however 
absence does not help in the exclusion of the diagnosis of TBM.   
 Infarct in the TBM meningitis had a pattern according to the work by Hsieh et. In the 
14 patients with TBM they studied 75% of infarction occurred in the ‘TB zone’ supplied 
by medial striate and thalamo perforating arteries. In them only 11% had infarction in the 
ischemic stroke zone supplied by lateral striate, anterior choroidal and thalamogeniculate 
   
Figure 9. TB infarct zone and Ischemic stroke infarct zone. 
3A. TB infarct zone supplied by supplied by medial striate and thalamo- 
perforating arteries; the head of the caudate nucleus, genu and anterior 
limb of internal capsule and anteromedial thalamus. 3B. Ischemic stroke 
infarct zone supplied by lateral striate, anterior choroidal and 
thalamogeniculate arteries; the lentiform nucleus, posterolateral 
thalamus and posterior limb of internal capsule. 
 
3A 3B 
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arteries. Among the control, 173 patients with noninflammatory ischemic stroke 29% had 
infarction in the IS zone and 11% occurred in the TB zone. 
A recent study which looked at the pattern of infarction in TBM concluded that the 
infarction occurs in perforator and cortical branches rather than ‘TB zone’ or ‘infarct 
zone’. 
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1.8. REASON FOR THE STUDY: 
Chen et al 2012 described a promising new rapid diagnostic tool for the diagnosis of 
tuberculous meningitis(6). This is a modified Zeihl-Neelsen staining technique for 
microscopy, which is based on the principle of staining the intracellular M. tuberculosis. 
Here CSF sample is cytospin on a poly-l-lysine-coated slide, which facilitate in 
distributing the immune cells evenly on the slide. A non-ionic surfactant Triton X-100 is 
used as the modification to the traditional Zeihl-Neelsen technique, which facilitate the 
stains to penetrate and stain the intracellular M. tuberculosis and also have been found to 
enhance the detection of extracellular M. tuberculosis.  Among the 48 CSF samples 
collected form 29 TBM culture confirmed patient. They found only 35 samples (35/48; 
72.92%) were culture positive and 8 (8/48; 16.67%) were Ziehl-Neelsen smear positive, 
while all of the samples (48/48; 0%) were positive by modified Ziehl-Neelsen stain. The 
sensitivity of culture was 72.92% (95% CI, 66.51 to 79.33) (n =35/48) compared to that 
of the modified Ziehl-Neelsen stain. (45) 
Feng et al 2014 have evaluated this modified Ziehl-Neelsen stain test against 
conventional Zeihl-Neelsen and mycobacterial culture. In TBM suspected patients who 
met the international diagnostic criteria for TBM as definite, probable, possible TB 
meningitis. They observed a sensitivity of 100% against mycobacterial culture  positive 
patients and 82.9 % against the clinical diagnostic gold standard and with a specificity of 
85%. (46) 
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Our proposed study is also designed to evaluate the diagnostic accuracy of this modified 
Zeihl-Neelsen technique for microscopy, using the consensus uniform research case 
definition criteria for TBM as the reference standard. Also, to assess the positive 
correlation between the definite TBM (culture /PCR positive) and modified Zeihl-
Neelsen staining to aid in early and prompt initiation of treatment. 
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MATERIAL AND METHODOLOGY 
4. STUDY DESIGN AND SETTING: 
We performed a prospective descriptive study, recruited 81 patients, who got admitted in 
the medical wards (13-Feb-2017 till 31-July-2018) of our institution, Christian Medical 
College, Vellore, in whom the treating physician suspected tuberculous meningitis. The 
study protocol was approved by the Institutional Review Board of Christian medical 
college, Vellore (IRB Min No: 10429). Written informed consent was obtained from all 
patients or their legal surrogates.  
Table 6- PICO statement 
P Patients age >18 years and suspected to have tuberculous meningitis by the 
treating physician 
I Modified Zeihl-Neelsen test. 
C Consensus uniform research case definition criteria for diagnosis of TBM 
O Post-test probability of diagnosis 
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5. INCLUSION CRITERIA 
1. Patients suspected to have tuberculous meningitis by the treating physician, 
for whom CSF testing for AFB smear by auramine-rhodamine stain, Xpert 
TB PCR or mycobacterial (MGIT or LJ) culture is ordered as the part of 
evaluation. 
2. Age ≥ 18 years 
 
6. EXCLUSION CRITERIA 
1. Definite contraindication for LP  
2. CSF WBC count <5 cells/μl 
3. Refusal of informed consent. 
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7. SAMPLE SIZE CALCULATION 
Considering a precision of 9, for a sensitivity of 82.9% and specificity of 85%, the 
sample size required was calculated as 130. 
 
 
Based on Feng G et.al (2014), the detection of sensitivity and specificity of AFB 
was 83% and 85% respectively. By assuming 9% precision with 95% confidence 
level, the required number of the study would be 67 diseased and 67 non-diseased 
cases. 
 
Sensitivity/Specificity of the new test (%) 83 83 83 83 83 
Precision (%)           5 8 7 7.7 9 
Desired confidence level (1- alpha) % 95 95 95 95 95 
No. of diseased subjects needed 217 85 111 91 67 
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All patients were consecutively and prospectively recruited. The population recruited are 
the patients, who are suspected to have tuberculous meningitis by the treating physician, 
and for whom CSF testing for either AFB smear by auramine-rhodamine stain, Xpert TB 
PCR, or MGIT/LJ culture is ordered as the part of evaluation. The principal investigator 
categorized these patients into definite TBM, possible TBM, probable TBM, and not 
TBM, based on the consensus uniform research case definition criteria for diagnosis of 
TBM. 
 After getting informed consent, 0.5 ml of the CSF specimens from the routine 
lumbar puncture for evaluation of meningitis, was labeled as study sample and sent to the 
clinical pathology department, where the proposed rapid diagnostic test modified Zeihl-
Neelsen microscopy technique was done. There, the samples were cytospun on to a poly-
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l- lysine-coated slide. Then the slides were fixed with 4% paraformaldehyde for 15 
minutes at room temperature. Then in batches (10-15 slides), the slides were 
permeabilized with 0.3% TritonX-100 for 30 minutes, before staining with carbolfuchsin 
containing 0.3% TritonX-100 and counterstained with methylene blue. Then the slides 
were sent to microbiology department lab, three hundred fields of each slide were 
examined by light microscopy and the numbers of fields and the type of leukocytes 
(neutrophils, lymphocytes, or monocytes) in which AFB are seen was documented. 
Positive slides were confirmed by independent review from another technician and 25% 
of slides was randomly selected for rereading. 
 Consensus uniform research case definition criteria for diagnosis of TBM, was 
done for all patients included in the study by the PI who was unaware of the results of the 
modified ZN smear. The study had a prospective diagnostic study design. 
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8. REFERENCE STANDARD 
  Consensus uniform research case definition criteria for diagnosis of TBM is 
taken as the reference standard. In that, the suspected TBM patients are classified in three 
groups according to clinical, laboratory and radiological criteria. Tuberculous meningitis 
classiﬁcation as follows 
i. Deﬁnite tuberculous meningitis: Patients should fulﬁll criterion A or B:  
A. Clinical entry criteria plus one or more of the following: acid-fast bacilli seen in 
the CSF; Mycobacterium tuberculosis cultured from the CSF; or a CSF positive 
commercial nucleic acid ampliﬁcation test. 
B. Acid-fast bacilli seen in the context of histological changes consistent with 
tuberculosis in the brain or spinal cord with suggestive symptoms or signs and CSF 
changes, or visible meningitis (on autopsy).  
ii. Probable tuberculous meningitis  
1. Clinical entry criteria plus a total diagnostic score of 10 or more points (when 
cerebral imaging is not available) or  
2. 12 or more points (when cerebral imaging is available) plus exclusion of 
alternative diagnoses. At least 2 points should either come from CSF or cerebral imaging 
criteria.  
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iii. Possible tuberculous meningitis. 
1. Clinical entry criteria plus a total diagnostic score of 6–9 points (when cerebral 
imaging is not available) or  
2. 6–11 points (when cerebral imaging is available) plus exclusion of alternative 
diagnoses. Possible tuberculosis cannot be diagnosed or excluded without doing a lumbar 
puncture or cerebral imaging. Not tuberculous meningitis  
iv. Not tuberculous meningitis: 
  Alternative diagnosis established, without a deﬁnitive diagnosis of tuberculous 
meningitis or other convincing signs of dual disease.  
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9. INDEX OR EXPERIMENTAL TEST  
 The experimental test is a modified Zeihl-Neelsen staining technique for 
microscopy; which is based on the principle of staining the intracellular M. tuberculosis. 
A non-ionic surfactant Triton X-100 is used as the modification to the traditional Zeihl-
Neelsen technique, which facilitate the stains to penetrate and stain the intracellular  
M. tuberculosis and also have been found to enhance the detection of extracellular  
M. tuberculosis. 
  Patient who met the inclusion criteria, after informed consent 0.5 ml of the 
CSF specimens from the routine lumbar puncture for evaluation of meningitis, was 
labeled as study sample and sent to the clinical pathology department, 
 Procedure of the modified Zeihl-Neelsen test, 
1. Load a poly-l-lysine-coated slide and filter paper to a cytospin chamber. 
2. Load 0.5 ml of CSF into a cytospin chamber with poly-l-lysine-coated slides. 
3. Centrifuge at 100g for 5 minutes in the cytospin cytology centrifuge apparatus. 
4. Fix the slides with 4% paraformaldehyde for 15 minutes at room temperature. 
5. Then rinse the slides in 0.3 % Triton X-100 solution for 30min and wash 3 times 
with 0.1M phosphate buffered solution 
6. Rinse the slides in 0.3 % Carbolfuschin containing 0.3 % TritonX-100 for 5 min 
and wash with distilled water 
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7. Decolorize the slides with 1% Acid alcohol until light pink and color stops 
running and wash with distilled water  
8. Finally, rinse the slides in working methylene blue for 30 seconds， and wash 
with distilled water. Dehydrate, clear, and coverslip. 
Then the slide was sent to microbiology laboratory, three hundred fields of each slides 
were examined under light microscopy and the numbers of fields and the type of 
leukocytes (neutrophils, lymphocytes, or monocytes) in which AFB were seen was 
documented. Positive slides were confirmed by, independent review from another 
technician and 25% of slides were randomly selected for rereading. 
 
10. TIMING 
  The turnaround time for index test is one day, and the turnaround time for 
some test in the reference standard result can vary from one days (if samples are positive 
by direct microscopy/ nucleic acid amplification result) to 8 weeks to wait for the CSF 
culture report. In our study, after fixation we did further processing in batches of 10-15 
slides. If the test result come positive in either of the arm, the treating physician was 
notified and it was the decision of the physician to initiate treatment depending on the 
index test results. 
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11. MINIMIZING BIAS 
Index test was interpreted independently of the reference standard and without 
knowledge of the results and the index test, which did not form the part of the reference 
standard.  
The microbiologist doing microscopy was not aware of the clinical details.  
The sample for the index test was processed at pathology lab and was coded with the 
study number. And the microbiologist performed the microscopy for modified Zeihl-
Neelsen, in batches. Microbiologist were completely blinded of the patient details, and 
other result while doing microscopy, thus minimizing the bias. 
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12. STATISTICAL METHODS 
Data was screened for outliers and extreme values using Box-Cox plot and histogram (for 
shape of the distribution). Summary statistics was used for reporting demographic and 
clinical characteristics.  The t-test was used for analysis of continuous data with normal 
distribution and Mann-Whitney U test for data with non-normal distribution with ASB. 
Chi-square test was performed for categorical variables and with ASB. Differences was 
considered significant at p<0.05. Multivariate analysis was performed based on the 
variables which were significant at bivariate analysis. All the statistical analysis was 
performed using SPSS 16.0. 
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1.9. STANDARD OPERATING PROCEDURE 
9. PROCEDURE OF THE MODIFIED ZEIHL-NEELSEN TEST 
PURPOSE:  
Used in the demonstration of acid-fast bacteria belonging to the genus 'mycobacterium', 
which include the causative agent for tuberculosis meningitis (TBM) patients. 
PRINCIPLE: 
The lipoid capsule of the acid-fast organism takes up carbolfuchsin and resists 
decolorization with a dilute acid rinse. The lipoid capsule of the mycobacteria is of such 
high molecular weight that it is waxy at room temperature and successful penetration by 
the aqueous based staining solutions (such as Gram's) is prevented. 
As the conventional Ziehl-Neelsen staining is severely handicapped by its low detection 
rate, ranging from 0 to 20% for CSF specimens for M. tuberculosis can hardly be stained 
by acid-fast dyes once it enters the cells. The modified Ziehl-Neelsen staining were 
performed to improve the detection of the presence of intracellular and extracellular acid-
fast bacteria from small CSF samples of TBM patients 
MATERIALS EQUIPMENT 
FMU-6 cytospin 
FMU-6 cytospin chamber 
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Microscope 
Poly-l-lysine-coated slides 
REAGENTS  
0.3 %Carbolfuschin containing 0.3 % TritonX-100 (100 ml) 
(1) Solution A:  Basic fuchsin             0.3 g 
  95% alcohol            10.0 ml 
(2) Solution B:  Phenol crystals            5.0 g 
             Distilled water           95 ml 
(3) Ziehl:  10 ml Solution A and 90 ml Solution B mix well 
(4) 30% Trion X-100 stock solution 
 
Triton X-100        28.2 ml 
Distilled water 0.1M PBS      71.8 ml 
（5）0.3 %Carbolfuschin containing 0.3 % Triton X - 100（ 100 ml ） 
99 ml Ziehl and 1 ml 30% Trion X - 100 stock solution mix well 
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1% Acid Alcohol (100 ml) 
Hydrochloric acid 1.0 ml 
70% Alcohol     99.0 ml 
Loeffier Methylene Blue (130 ml) 
(1) Solution A:   Methylene Blue Stock     0.3 g 
95% Alcohol           30.0 ml 
(2) Solution B:   0.01 % KOH 100 mL  
                     KOH                 0.01 g 
                     Distilled water         100 ml 
      
(3) Loeffier Methylene Blue: 
               Solution A and Solution B mix well     
0.3 % TritonX-100 Solution（100 ml） 
Triton X - 100           0.3 ml 
0.1M PBS            100 ml 
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4% paraformaldehyde（1000ml ， pH 7.4 ） 
Paraformaldehyde                40g 
Na2HPO4·12H2O               28.99 g 
NaH2PO4·2H2O                  2.96 g 
Distilled water             add to 1000ml  
0.1M PBS (phosphate buffered solution) （1000ml， PH7.4 ） 
Na2HPO4·12H2O           28.99 g 
NaH2PO4·2H2O            2.96 g 
Distilled water             add to 1000ml  
 
PROCEDURE 
Sample collection  
1. Put a poly-l-lysine-coated slide and filter paper to an FMU-6 cytospin chamber 
2. Load 0.5 ml of CSF into an FMU-6 cytospin chamber with poly-l-lysine-coated 
slides 
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3. Centrifuge the FMU-6 cytospin chamber, at 100g for 5 minutes in the FMU-6 
cytospin cytology centrifuge apparatus and then take the slide down.   
 
Fixation 
Fix the slide with 4% paraformaldehyde for 15 minutes at room temperature  
Staining procedure 
1. Rinse the slide in 0.3 % Triton X-100 solution for 30min and wash 3 times with   
0.1M phosphate buffered solution. 
2. Rinse the slide with 0.3 % carbolfuschin containing 0.3 % TritonX-100 for 5 min 
and wash with distilled water. 
3. Rinse the slide with 1% Acid alcohol until light pink and color stops running and 
wash with distilled water  
4. Rinse the slide with working methylene blue for 30 seconds, and wash with 
distilled water. Dehydrate, clear, and coverslip. 
Interpretation: 
Acid-fast bacilli                                 bright red.  
Non- acid-fast bacilli：                           blue 
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RESULTS 
13. BASELINE CHARACTERISTICS 
The mean age of patients in the TBM group was 38.8 years and SD (15). There was male 
predominance 47/62 (75.5%) among the patient who had TBM. Table 7 provides the 
demographic and the clinical features of the patient included in the analysis.  
Table 7-Demographic and clinical details 
 Definite 
TBM (n=16) 
Probable TBM 
(n=27) 
Possible TBM 
(n=19) 
Non TBM 
(n=19) 
Age in Years (mean±𝑆𝐷) 36.6(13.6) 41.9(15.5) 34.1(15.2) 44(15.4) 
Male: Female 10:16 22:5 15:4 13:6 
GCS 14 (6-15) 13 (7-15) 15(12-15) 13(5-15) 
MRC 
    
I 8 (50%) 12(50%) 9 (75%) 0 
II 4(25%) 7(29.2%) 1(8.3%) 0 
III 4(25%) 5(20.8%) 2(16.7%) 0 
Altered consciousness 8 (50%) 11(40.7%) 3(15.8%) 2(10.5%) 
Symptoms more than 5 days 16 (100%) 27(100%) 18(94%) 8(42%) 
Focal neurological deficits 4 (25%) 6(22.2%) 2(16%) 0(0) 
Cranial nerve palsy 4(25%) 5(18.5%) 2(10.5%) 2(10.5%) 
TBM-Tuberculous meningitis, MRC- Medical Research Council (MRC) 
disease severity grade. 
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14. STARD DIAGRAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10-STARD diagram 
TBM-Tuberculous meningitis, MGIT-, MZN-Modified Zeihl-Neelsen test 
Eighty-one (81) patients admitted in the Christian Medical College Hospital, 
Vellore from February 2017 till July 2018 were included in the analysis. Among them, 16 
were classified as definite TBM, 27 as probable TBM, 19 as possible TBM and 19 as 
Eligible Participants 
N=81 
a 
MZN test 
N=81 
MZN negative 
N=78 
MZN positive 
N=3 
Reference standard 
N=78 
Reference standard 
N=3 
Definite TBM 13 
Probable TBM 27 
Possible TBM 19 
Non TBM 19 
Definite TBM 3 
Probable TBM 0 
Possible TBM 0 
Non TBM 0 
66 
 
“not TBM,” based on the consensus uniform research case definition criteria. Table 7 
summarizes the frequency of various test done in each category. 
 
Table 8-Frequency of various diagnostic test performed in the CSF sample 
Various diagnostic test Definite 
TBM(n=16) 
Probable 
TBM(n=27) 
Possible 
TBM 
(n=19) 
Non 
TBM((n=19)) 
MZN Done 16 (100%) 27 (100%) 19 (100%) 19 (100%) 
 Not Done 0 0 0 0 
Xpert MTB/RIF Done 14 (87.5%) 21 (77.8%) 13 (68%) 10 (52.6%) 
Not Done 2 (1.5%) 6 (22.2%) 6 (31.6%) 9 (47.4%) 
MGIT Done 16(100%) 25 (92.5%) 17 (89.4%) 15 (78.9%) 
 Not Done 0 2 (7.4%) 2 (10.5%) 4 (21.1%) 
 Awaited results 2 6 (22.2%) 3 (15.8%) 2 (10.5%) 
Auramine-
rhodamine 
stain 
Done 16 (100%) 25 (92.5%) 17 (89.4%) 15(78.9%) 
 Not Done 0 2 (7.4%) 2(10.5%) 4 (21.1%) 
 
For the analysis of the diagnostic performance of each test, if only the particular test was 
done for the patient, were included in the analysis. In case of MGIT some result was 
awaited while the analysis was done, and those were excluded for the analysis of 
diagnostic performance of MGIT.  
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15. VENN DIAGRAM 
 
Figure 11-Venn diagram showing the Definite TBM cases. 
The Venn diagram displays 16 participants with tuberculosis detected in 
CSF by 
each diagnostic test and the overlap between tests. 
MZN-Modified Zeihl-Neelsen, MGIT- mycobacteria growth indicator tube. 
Among the definite TBM group, 13 patients were positive by MGIT culture, 9 patients 
were positive by Xpert MTB/RIF and, 3 by auramine-rhodamine stain (a case of definite 
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TBM could have more than 1 positive result). Figure 11 Venn diagram depicts the 
overlap between various diagnostic test among the definite TBM patients. Exclusive 
single tests positive were 6 for MGIT, 2 patients were exclusively Xpert MTB/RIF was 
positive and 1 patient for auramine-rhodamine stain. For that 1 auramine-rhodamine stain 
positive patient the MGIT report is awaited. 
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16. LAB PARAMETERS 
Table 9 Laboratory parameters 
Laboratory Parameters 
Mean (Range) 
Definite 
TBM 
Probable 
TBM 
Possible 
TBM 
Non TBM 
CSF WBC cells/μl 
(Range) 
211 (20-810) 203 (3-820) 171 (1-920) 349 (12-3480) 
Polymorphs% (Range) 16 (0-93) 14 (1-70) 16 (0-84) 25 (1-93) 
Lymphocytes % 60 (2-99) 82 (28-99) 74 (0-98) 69 (4-96) 
Monocytes % 4 (0-16) 2 (0-13) 3 (0-15) 5 (0-20) 
Glucose mg/dl 48 (12-112) 52 (21-105) 59 (24-91) 63 (5-149) 
Protein mg/dl 219 (33-564) 280 (55-1100) 135 (38-357) 166 (56-542) 
 
 
Among the TBM patient n=62 (definite, probable and possible) mean CSF WBC cell 
counts was 195 cell/μl (SD 206.4), mean CSF polymorph was 62% (SD 24%), mean 
lymphocyte was 74 % (SD 26%), mean CSF monocyte was 3.13% (SD 4%). The CSF 
glucose was 52 mg/dl as compared 63 mg/dl in the non-TBM group, mean CSF protein 
was 220 mg/dl as compared to 166 mg/dl in non TBM group. Table 9 summarize the 
main the laboratory features in each group. 
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17. IMAGING 
Table 10-Imaging features of the patients 
  Definite 
TBM(n=16) 
Probable 
TBM(n=27) 
Possible 
TBM (n=19) 
Non 
TBM((n=19)) 
CNS     
Hydrocephalus 6 (37.5%) 10 (37.0%) 1 (5.30%) 0 
Basal meningeal 
enhancement 
9 (56.0%) 22 (81.0%) 3 (15.8%) 1 (5.30%) 
Ring-enhancing lesions 5 (31.3%) 8 (29.6%) 2 (10.5%) 1 (5.30%) 
Brain infarct 3 (18.8%) 10 (37.0%) 0 1 (5.30%) 
Pre-contrast hyper density 3 (18.8%) 15 (55.6%) 2 (10.5%) 2 (10.5%) 
TB outside CNS     
  Signs of tuberculosis * 0 4 (14.8%) 0 0 
  Miliary tuberculosis * 4 (25.0%) 3 (11.1%) 0 0 
  CT/MRI. Ultrasound 
evidence of TB 
1 (6.3%) 6 (22.2%) 0 0 
TBM-Tuberculous meningitis, CNS-Central nervous system, * In Chest X-ray, 
TB-Tuberculous, CT- Computed tomography, MRI-Magnetic resonance 
imaging. 
Among the TBM group n=62 (definite, probable and possible group), 17 (27.4%) had 
hydrocephalus, 34(54.8%) had basal meningeal enhancement, 15 (24.2%) had 
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tuberculoma, 13 (21%) had infarcts, 20 (32.3%) had precontrast-hyperdensity.  Table 10 
gives the frequency of various radiological abnormalities in the different groups. 
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18. HIV STATUS 
 
Figure 12-HIV Distribution. 
There were total 9 HIV positive patients distributed as shown in the figure. 
 
There were 9 patients who were HIV positive.  
 
  
Definite TBM, 3
Probable TBM, 3
Posible 
TBM, 1
Non TBM, 2
HIV DISTRIBUTION
Definite TBM Probable TBM Posible TBM Non TBM
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19. ALTERNATE DIAGNOSIS 
 
 
Figure 13-Non TBM Diagnosis 
There was 13 patient who was categorized as non TBM, Cryptococcal 
meningitis 2, Scrub typhus 2, Streptococcal pneumonia meningitis 2, 
Toxoplasmosis 1, EBV positive 1, Invasive mucor 1and with unknown 
diagnosis 4. 
 
The Streptococcal pneumonia meningitis was culture proven. Cryptococcal 
meningitis patient was culture, India ink and cryptococcal antigen test positive for 
Cryptococcus neoformans. Scrub typhus diagnosis was confirmed with IgM ELISA 
positive for scrub typhus. The CNS toxoplasmosis patient was a HIV positive and had 
IgG for Toxoplasma was positive and the imaging features were suggestive of 
Cryptococcal 
Meningitis, 2, 15%
Scrub Typhus, 2, 15%
Strep Pneumonia 
Meningitis, 2, 15%
Toxoplasmosis, 1, 8%
EBV positive, 1, 8%
Invasive mucor, 1, 8%
Unknown, 4, 31%
Non TBM diagnosis (n=13)
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toxoplasmosis. Invasive rhino- cerebral mucormycosis patient was culture and biopsy 
proven. There was no identifiable etiology in 4 patients. 
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20. DIAGNOSTIC ACCURACY OF MZN AND XPERT  
Table 11- Results of various diagnostic test. 
Reference standard MZN Xpert MGIT Auramine 
rhodamine  
 
+ - + - + - + - 
Definite, probable or 
probable TBM 
3 59 8 40 13 34 3 55 
Not TBM 0 19 0 10 0 13 0 15 
Definite or probable  3 40 8 27 13 20 3 38 
Not TBM 0 19 0 10 0 13 0 15 
Definite TBM 3 13 8 6 13 1 3 13 
Not TBM 0 19 0 10 0 13 0 15 
TBM-Tuberculous meningitis, MZN- modified Zeihl-Neelsen. MGIT- mycobacteria 
growth indicator tube. 
 
Table 11 summarizes the result of the various diagnostic test performed against the 
reference standard. For MZN analysis all 81 patient were included. Only 60 patients were 
included in the analysis of MGIT as it was not done in 8 patients and in 13 patients the 
final results were awaited. For Xpert MTB/RIF analysis 58 patient were included for the 
analysis. 
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Table 12-Diagnostic accuracy of Modified Zeihl-Neelsen and Xpert MTB/RIF 
Reference 
standard 
Diagnostic 
accuracy 
MZN (%) 95% CI Xpert TB (%) 95% CI 
Definite, probable 
possible TBM 
Sensitivity 4.84 (3/62) 1-13.5 16.6 (8/48) 7.5-30.2 
Specificity 100 (19/19) 82.3-100 100 (10/10) 69.1-100 
PPV 100 (3/3) 
 
100 (8/8) 
 
NPV 24.36 
(19/78) 
23.3-25.4 20 (10/50) 18.0-22.1 
Definite, probable 
TBM 
Sensitivity 6.98 (3/43) 1.4-19 22.8 (8/35) 10.4-40.1 
Specificity 100 (19/19) 82.3-100 100 (10/10) 69.1-100 
PPV 100 (3/3) 
 
100 (8/8) 
 
NPV 32.2(19/59) 30.4-34 27.0 (10/37) 23.6-30.7 
Definite TBM Sensitivity 18.75 (3/16) 4.0-45.6 57.1 (8/14) 28.8-82.3 
Specificity 100 (19/19) 82.3-100 100 (10/10) 69.1-100 
PPV 100 (3/3) 
 
100 (8/8) 
 
NPV 59.38 
(19/32) 
53.6-64 62.5 (10/16) 47.6-75.3 
 
TBM-Tuberculous meningitis, MZN- modified Zeihl-Neelsen, PPV- Positive 
predictive value, NPP-Negative predictive value. 
Among the 81 suspected TBM patients, 3 tested positive with MZN culture, Table 12 
summarizes the diagnostic accuracy of MZN and Xpert MTB/RIF. The sensitivity of the 
MZN test was found to be 4.84% with a 95% CI; 1-13.5; 3/62, as compared to a reference 
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standard of definite probable and possible TBM. The sensitivity was 18.75% with a 95% 
CI 4-45.6; 3/16, for definite TBM category. The specificity was 100%. 
Xpert MTB/RIF had a sensitivity of 16.6 % (95% CI 7.5-30.2; 8/48), with definite, 
possible and probable TBM as reference standard. With definite TBM as the reference 
standard Xpert MTB/RIF, had a sensitivity of 57.1% (95% CI of 28.8-82.3; 8/16). The 
specificity was 100%. 
Table 13 summarizes the diagnostic accuracy of MGIT and auramine-rhodamine stain. 
MGIT had a sensitivity of 27.6 (95% CI 15.6-42.6;13/47), with definite, possible and 
probable TBM as reference standard. With definite TBM as reference standard MGIT, 
had a sensitivity of 92.8%; 95% CI 66.1-99.8; (13/14). The specificity was 100%. 
Figure 14 shows the sensitivity comparison between the diagnostic tests. 
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21. DIAGNOSTIC ACCURACY OF MGIT AND AURAMINE-RHODAMINE STAIN 
Table 13 Diagnostic accuracy of MGIT and Auramine-rhodamine stain. 
Reference 
standard 
Diagnostic 
accuracy 
MGIT (%) 95% CI Auramine-
rhodamine (%) 
95% CI 
Definite, 
probable, 
probable TBM 
Sensitivity 27.6 (13/47) 15.6-42.6 5.2 (3/58) 1.0-14.3 
Specificity 100 (13/13) 75.2-100 100 (15/15) 78.2-100 
PPV 100 (13/13) 
 
100 (3/3) 
 
NPV 27.6 (13/47) 24.2-31.3 21.4 (15/70) 20.4-22.4 
Definite, 
probable TBM 
Sensitivity 39.3 (13/33) 22.9-57.8 7.3 (3/41) 1.5-19.9 
Specificity 100 (13/13) 75.2-100 100 (15/15) 78.-100 
PPV 100 (13/13) 
 
100 (3/3) 
 
NPV 39.3 (13/33) 33.0-46.1 28.3 (15/53) 26.5-30.0 
Definite TBM Sensitivity 92.8 (13/14) 66.1-99.8 18.7 (3/16) 4.0-45.6 
 
Specificity 100 (13/13) 75.2-100 100 (15/15) 78.2-100.0 
 
PPV 100 (13/13) 
 
100 (3/3) 
 
 NPV 92.8 (13/14) 66.2-98.8 53.5 (15/28) 47.6-59.3 
TBM-Tuberculous meningitis, MZN- modified Zeihl-Neelsen, PPV- Positive 
predictive value, NPP-Negative predictive value. 
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Figure 14-Sensitivity comparison between the various diagnostic test 
Comparison of sensitivities of MZN, MGIT, Xpert MTB/RIF and auramine-
rhodamine stain against reference standard A.  Definite, probable and 
possible TBM and Definitive probable TBM. B. Definite TBM.  
TBM-Tuberculous meningitis, MZN- modified Zeihl-Neelsen. 
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DISCUSSION: 
TBM is associated with severe mortality and morbidity and the diagnosis is challenging. 
Prompt initiation of treatment is crucial in the disease outcome. (6,8). There are no good 
rapid diagnostic tests to microbiologically confirm the diagnosis of TBM. Many 
diagnostic algorithms are developed for early diagnosis. In current study we evaluated the 
diagnostic performance of Modified Zeihl-Neelsen using the consensus uniform research 
case definition criteria for the TBM diagnosis as Gold standard. 
We found the sensitivity of Modified Zeihl-Neelsen to be only 5% (3/81), but the 
specificity was 100%. The sensitivity was 6.98 % (3/43) when considering only the definite 
and probable TBM cases as the reference standard. The sensitivity improved to 18 % when 
considering only definite TBM cases as reference standard.   
Identification of AFB in MZN was easier in positive samples, as the pink AFB stand out 
against the blue background (Figure 15).  
Auramine-rhodamine stain had a similar sensitivity 7% (3/58) and 100% specificity. 
Sensitivity improved to 18.7% when considering only definite TBM as reference 
standard. Both MZN and auramine-rhodamine stain detected the AFB in two samples and 
1 sample each was exclusively detected individually (Figure 11). 
MGIT had a sensitivity of 27.6 (13/47) and the specificity was 100%. The sensitivity was 
39.3 (13/33) considering definite and probable TBM as reference standard. The sensitivity 
81 
 
improved to 92.8 (13/14) considering definite TBM as reference standard (MGIT was 
also included in the composite outcome). 
The sensitivity of Xpert TBM/RIF was found to be modest 16.6 (8/48), however more 
than that of MZN and auramine-rhodamine stain. Against a definite TBM Xpert 
TBM/RIF sensitivity was found to be 57.1 (8/14). The advantage of using the Xpert 
TBM/RIF system being the detection of rifampicin resistance. If a drug resistant TBM is 
not promptly initiated on appropriate medication, it carries has higher mortality before 
the availability full culture report with the antibiotic sensitivity report. 
MGIT culture has a sensitivity threshold of detecting about ten bacilli (colony-forming 
units [CFU] per mL) whereas Xpert has a threshold of about 100 CFU/mL.Xpert Ultra 
has the limit of detection of about 10 CFU/mL15 
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Figure 15- Modified Zeihl-Neelsen stain 
A&B Shows AFB pink color. C. shows intracellular AFB. 
Feng et all in 2014 evaluated the diagnostic accuracy of MZN and demonstrated a 
sensitivity of 82.9% and the conventional ZN stain had a sensitivity of 3.3% against the 
consensus score of definite, probable and possible TBM as Gold standard. In the same 
series, considering the definite TBM as the gold standard, MZN had 100% sensitivity and 
conventional ZN had a sensitivity of 21%. Conventional ZN reports are comparable with 
their report.  
A B 
C 
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Table 14-Baseline characteristics between studies 
 TBM Non TBM 
 Feng 2014 
n=240 
Wang 2016 
n=267 
Present study 
N=62 
Feng 
2014 
N=40 
Wang 
2016 n=49 
Our 
Study 
N=19 
Clinical details       
Age in years* 30.6 29.6 38.8 41 36.75 44.6 
MRC       
I 162/267(67.5%) 127/267 (47%) 29/52 (55.8%)    
II 54/267(22.5%) 48/267 (17%) 12/52 (23.1%)    
III 20/267(8.3%) 92/267 (34%) 11/52 (21%)    
Imaging       
Hydrocephalus  37/267 
(13.85%) 
  3/49 
(6.1%) 
 
Basal Meningitis  33/267 
(12.35%) 
34/62   
(54.8%) 
 5/49 
(10.2%) 
1/19 
(5.3%) 
Infarcts  43/267(16.1%) 13/62 (21%)   1/19 
(5.3%) 
Lab parameters       
WBC cells/μl* 90 104 195 51 25 349 
Neutrophils (%) 9 10.6 20.53 4 12 24.95 
Lymphocyte (%)  49.6%  74.27% 29%  69.42% 
Monocytes (%) 7.3% 9.6% 3.13% 4% 16.5% 4.95% 
Glucose mg/dl* 44.3  52.69 55.8  63.47 
Protein mg/dl* 900  220.13 600  166.11 
*Mean, WBC- White blood cells, MRC-Modified research council, TBM-
Tuberculous meningitis. 
 
In 2016, Ting Wang also has demonstrated a higher sensitivity of 61.8% with a 
sub optimal specificity of 71.4% when considering definite, probable and possible TBM 
as the gold standard. Considering culture positive cases, MZN had a sensitivity of 100% 
and had specificity of 51.6%. The high false positive rate was attributed to the identifying 
artifact as AFB.  
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The baseline characteristics of these two studies were comparable. Table 14 summarize 
the various demographic, clinical, radiological and biochemical features. The base line 
characteristics were comparable across the studies. 
In our study we could not demonstrate such high sensitivity.  Our results were almost 
correlating with auramine-rhodamine stain. We would wait for further work to confirm 
our findings. 
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LIMITATION 
At times consecutive patients could not be recruited. The slides were fixed and the 
staining was done in batches. Technically it should not make any difference as the slides 
are fixed. Non-availability of a robust reference standard also limits the development of 
rapid diagnostic stool with good accuracy.  
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CONCLUSION 
We evaluated the diagnostic accuracy of Modified Zeihl-Neelsen staining technique for 
the diagnosis of TBM. We found that, Modified Zeihl-Neelsen did not improve the 
sensitivity in comparison to smear microscopy, and did not improve the diagnostic yield. 
However, the identification of the AFB in the positive smear patient was easier for the 
microscopist with MZN. Need of a cytospin machine could limit the possibility of MZN 
replacing auramine-rhodamine stain. Further rapid diagnostic tests with good diagnostic 
accuracy for TBM diagnosis should be developed. 
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ABSTRACT 
Background: Rapid diagnosis of tuberculous meningitis (TBM) is crucial for prompt 
initiation of treatment. We are evaluating the diagnostic accuracy of modified Zeihl-
Neelsen stain a newer diagnostic tool for the diagnosis of TBM, using consensus uniform 
research case definition criteria as reference standard. 
Methods: Patient with a clinical diagnosis of TBM admitted in Christian Medical 
College Vellore, India, were prospectively enrolled from February 2017 till July 2018. 
Cerebrospinal fluid (CSF) samples of the patients were evaluated using the modified 
Zeihl-Neelsen technique, auramine-rhodamine stain, Xpert MTB/RIF, MGIT, 
biochemical tests along with clinical and radiological assessment.  
Results: Among the eighty-one patients, 16 were classified as definite TBM, 27 as 
probable TBM, 19 as possible TBM and 19 as “not TBM,” based on the consensus 
uniform research case definition criteria. Considering ‘definite, probable and possible 
TBM’ and ‘no TBM’, the MZN has a sensitivity of 4.8% (3/81) and a specificity of 
100%, Xpert had a sensitivity of 16.6 % (8/48), auramine-rhodamine test had a sensitivity 
of 5.2% (3/58), MGIT had a sensitivity of 27.6% (13/47). 
Conclusion: MZN confirms the diagnosis of TBM rapidly, however it has not added to 
the diagnostic yield. Need of cytospin machine would limit the possibility of replacing 
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auramine-rhodamine test. Further rapid diagnostic test with good diagnostic accuracy 
should be developed. 
Keywords: tuberculosis meningitis, TBM, Modified Ziehl-Neelsen stain, MZN, Xpert 
MTB/RIF, MGIT.  
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1.11. INFROMATION SHEET 
1. ENGLISH 
Department of Medicine 
 Christian Medical College Vellore 
Tuberculous Meningitis Study-Patient Information sheet 
What is tuberculous meningitis? 
 Tuberculous meningitis is an infection caused by a bacterium called Mycobacterium 
tuberculosis.  This is type of brain fever affecting the meninges (coverings of the brain). This 
bacterium M. tuberculosis is a slow growing bacterium. The covering of the brain plays 
important protective role to the brain. It provides anchoring, nourishment through the 
cerebrospinal fluid that circulates within the space in the covering, also form scaffolding for 
the blood vessels and many other. When this covering is infected, most of these function 
gets compromised, and can result in the symptom and complication related with 
tuberculous meningitis. 
What are all the symptoms and complication? 
 Adult patients often present with the classic meningitis (inflammation of the 
meninges) symptoms of fever, headache, stiff neck, with focal neurological deficits, 
behavioral changes and change in consciousness. Patient can complaint of being unwell of 
over two weeks prior to the development of meningeal irritation. 
The most common complications are obstructive hydrocephalus (abnormal dilation 
of the ventricle spaces of the brain), stroke, cranial nerve weakness, epileptic seizures, 
diabetes insipidus, tuberculoma (mass in the brain), myeloradiculopathy (spinal cord 
involvement). Neurological and systemic complications of tuberculous meningitis were 
common and were important causes of death and long-term disability due to this deadly 
disease. 
How it spreads? 
 Usually it tuberculosis enters through droplet inhalation and affect the lungs mostly 
causing pulmonary tuberculosis. Then from there it is spread to other distant organs 
including the coverings of the brain. Sometime the lung infection is not very marked but 
still can spread to other organs. 
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How it is diagnosed? 
 The diagnosis can be confirmed if M. tuberculosis can be demonstrated in the 
cerebro spinal fluid (fluid that circulated in the spaces and within the coverings of the 
brain). Most of the bacterial infection can be diagnosed by direct microscopy, culture i.e. 
growing the bacterium artificially and other sophisticated molecular techniques. But in M. 
tuberculosis being a slow growing bacterium all the test has varying ability in diagnosing 
the disease. One gold standard confirmatory test called culture i.e. Growing the bacterium 
artificially sometime takes 2 weeks to sometime up to 8 weeks for the result.  Due to the 
limitation of the available diagnostic tests, most often diagnosis is usually made on clinical 
evidence, combines with other supportive clinical, laboratory, and radiological findings. 
Is treatment available for TBM? 
 Yes, medication are available however early diagnosis and prompt initiation of 
treatment is required to prevent complication. 
What is this study about? 
 This study evaluates a rapid microscopy-based test for the diagnosis of tuberculous 
meningitis in the cerebro-spinal fluid sample. This study aimed at validating this new test 
for microbiological confirmation of tuberculous meningitis and thereby aid in early and 
prompt initiation of treatment. 
What type of sample is needed? 
This test is performed with 0.5 ml of cerebro-spinal fluid (CSF). CSF is collected through 
lumbar puncture, which is a procedure normally done for any meningitis patients, for diagnosis 
unless contraindicated. In an adolescent and adult up to 17 ml CSF can removed at one time. 
Is there any complication related with the sampling technique? 
 Patient can get post lumbar puncture head ache. Which is self-limiting and usually 
doesn’t require any specific treatment. 
What will happen if you develop study related injury? 
We do not expect any injury to happen but if you do develop, if you develop any 
complication these will be treated free of cost to you. However, we are unable to provide 
monetary compensation to you. 
Will your personal details be kept confidential? 
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 Yes. Your personal details will be kept confidential. If the results if the study are 
published in a medical journal, you will not be identified by name in any publication or 
presentation of the study results. However, your medical notes may be reviewed by people 
associated with the study. 
Can I withdraw from this study after it starts?  
Your relative’s participation in this study is entirely voluntary. You can withdraw consent 
for the study at any time and this will not affect your relative’s care and treatment.  
 
If you have any further questions, please contact: 
Dr Jemin J Webster 
Department of General Medicine 
Christian Medical College, Vellore 632002 India 
Tel: 9894851282 
Email: jemin.webster@cmcvellore.ac.in 
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Informed Consent form to participate in a research study 
Study Title: Rapid diagnosis of tuberculous meningitis; Evaluation of a modified Zeihl-
Neelsen stain for demonstrating Mycobacterium tuberculosis. ‘TBM ZeihlSon Study’ 
 
Study Number: ____________ 
Subject’s Name: _________________________________________ 
Date of Birth / Age: __________________________ 
(i) I confirm that I have read and understood the information sheet dated 18-11-
2016 for the above study and have had the opportunity to ask questions.   [  ] 
 
(ii) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [  ] 
 
(iii) I understand that, the Ethics Committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or 
published. [  ] 
(iv) I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). [  ] 
 
(v) I consent to allow the researchers, to process my/___________(Relationship) CSF 
fluid sample for the study purpose. [  ] 
 
(vi) I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
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Signatory’s Name: _________________________________         Signature:  
 
 
Or 
 
 
 
 
 
Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
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Signature (or) thumb impression of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name of the Witness: ______________________________ 
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1.12. BANGLA 
 
Rapid diagnosis of tuberculous meningitis; Evaluation of a modified Zeihl-Neelsen stain 
for demonstrating Mycobacterium tuberculosis. ‘TBM ZeihlSon Study’ 
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1. TAMIL 
மருத்துவப் பிரிவு 
கிறிஸ்துவ மருத்துவக் கல்லூரி வவலூர் 
காச வ ாய் முளைக்காய்சச்லின் ஆய்வு; வ ாயாைிகை் தகவல் படிவம். 
காச ந ாய் மூளைக்காய்சச்ல் என்றால் என்ன? 
  ளைக்நகாபக்டீரியை் டுயுபரக்ுநைாசிஸ் என்ற ஒரு வளகயான பாக்டீரியா 
கிருமியால் உண்டாகுை் ந ாய் தான் காசந ாய் மூளைக்காய்சச்ல் என்பது. 
மூளைளய சுற்றியுை்ை உளறசச்வ்வுகளை பாதிக்கின்ற ஒரு வளகயான 
முளைக்காய்சச்லாகுை் இ ்த ந ாய். ளைக்நகாபக்டீரியை் டுயுபரக்ுநைாசிஸ் 
என்பது மைதுவாக வைரக் கூடிய ஒரு பாக்டீரியாவாகுை். மூளையின் 
உளறசச்வ்வுகை் மூளைளய பாதுகாப்பதில் மபருை் பங்குவகிக்கின்றன. 
மூளைச ்சவ்வுகளுக்கிளடயில் பரவி ஓடிக் மகாண்டிருக்கின்ற மூளைத் 
தண்டுவட திரவை், மூளைக்கு ஊட்டசச்த்து அைிப்பதுை், மூளைக்குை் மூளையின் 
இரத்த  ாைங்களுக்குை் உறுதியான கட்டுைானை் மகாடுப்பதுை், என்ற பல 
முக்கிய அை்சங்கை் கூடிய இ ்த மூளைச ்சவ்வுகைில் மதாற்று ந ாய் 
ஏற்பட்டால், பல மசயல்பாடுகை் பாதிப்பளட ்து சிக்கல்கை் ந ரிடக் கூடுை். 
அறிகுறிகை் ைற்றுை் அபாய விளைவுகை் என்மனன்ன? 
  காய்சல், தளலவலி, கழுத்து இறுக்கை், உடல் தைரச்ச்ி,  டவடிக்ளகயில் 
ைாற்றை், ையக்க ிளல என பல்நவறு அறிகுறிகை் முளைக்காய்சச்லில் வரக் 
கூடுை். மூளை ிரக்் நகாளவ, பக்கவாதை், ரை்பு தைரச்ச்ி, வலிப்பு,  ீரிழிவு 
ந ாய், கட்டி நபான்ற விளைவுகை் வருவநதாடு ந ாயாைி உயிரிழக்குை்  ிளல 
கூட ந ரிட வாய்ப்புை்ைது. 
எவ்வாறு பரவுகிறது? 
  காசந ாய்க் கிருமி சுவாசத்தின் மூலைாக காற்றிலிரு ்து நுளரயீரளல 
பாதிதீது, ைற்ற உடலுறுப்புகளையுை் பாதிக்கின்றது. சில சையங்கைில் 
நுளரயீரளல மபரிதாக பாதிக்காைநலநய, ைற்ற உறுப்புகளுக்கு பரவுை் வாய்ப்பு 
இருக்குறது. 
எப்படி கண்டுபிடிக்கப்படுகிறது? 
  மூளைளய சுற்றி உை்ை மூளைத் தண்டுவட திரவத்ளத நுன்ந ாக்கியில் 
ஆய்வு மசய்வதன் மூலை், காசந ாய்க் கிருமிகளைக் கண்டுபிடிகிகலாை். 
கல்சச்ர ்எனறளழக்கபடுை் மசயற்ளக பக்டீரியா வைரப்்பு முளறயின் 
மூலைாகவுை் கண்டுபிடிக்கலாை். காசந ாய்க் கிருமிகை் மைதுவாக வைரக் 
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கூடிய தன்ளை மகாண்டபடியால் 2 வாரத்திலிரு ்து 8 வாரங்கை் வளர 
காத்திரு ்தால் ைட்டுநை கல்சச்ர ்நதரவ்ன் முடிவுகை் கிளடக்குை். 
இ ்த ந ாய்க்கு சிகிசள்ச உண்டா? 
  ஆை், தக்க சையத்தில் கண்டுபிடித்து சிகிசள்ச மசய்வதன் மூலை் 
விளைவுகளை தவிரக்்க முடியுை். 
இ ்த ஆய்வின் ந ாக்கை் என்ன? 
  காசந ாய்க் கநுமிகளை நுண்ந ாக்கயில் துரிதைாக கண்டறியுை் ஒரு 
முளறளய ைதிப்பீட்டு ஆய்வு மசய்து, அதன் முலை் விளரவாக 
மூளைக்காய்சச்ளல கண்டு பிடிப்பநத இ ்த ஆய்வின் ந ாக்க ைாகுை். 
இ ்த ஆய்வு எவ்வாறு மசயல்படுகிறது? 
  தண்டு வடத்தில் ஊசியின் மூலை் மூளைத் தண்டுவட திரவதள்த (0.5 மி.லி 
அைவு) எடுதத்ு இ ்த பரிநசாதளன மசய்யப் படுை். சராசரியாக 17 மி.லி 
திரவத்ளத ஒநர ந ரத்தில், எ ்த பாதப்புை் இல்லாைல் எடுக்கலாை்.  
இ ்த ஆய்வினால் ஏதாவது பாதிப்பு ஏற்பட வாய்ப்புை்ைதா? 
  சாதாரணைாக எ ்த ஒரு மூளைக் காய்சச்லிலுை் மசய்யப்படுகின்ற, 
மூளைத் தண்டுவட திரவ பரிநசாதளனயாை், இ ்த நதரவ்ுமுளறயில் எ ்த 
பாதிப்புை் எதிரப்ாரக்்கப்படவில்ளல. 
தண்டுவடத்தில் ஊசி இடுவதனால் பாதிப்பு ந ரிட வாய்ப்பிருக்கிறதா? 
  தளலவலி ஏற்பட வாய்ப்பிருகிறது. ஆனால் எ ்த வித சிகிசள்சயுை் 
நதளவயில்ளல. 
தனி பர ்விவரங்கை்  ை்பகைாக பாதுகாக்கப்படுைா? 
  ஆை், தங்களுளடய தனி பர ்விவரங்கை்  ை்பகைாக ளவதத்ுக் மகாை்ைப் 
படுை். இ ்த ஆய்வின் முடிவுகை் ைருத்துவ ஆய்விதழ்கைில் 
மவைியிடப்பட்டாலுை், தங்கைின் மபயர ்ைற்றுை் விவரங்கை் மவைியிடப்படாது. 
எங்கிலுை் தங்களுளடய ைருதத்ுவ குறிப்புகளை ைட்டுை் இ ்த ஆய்வில் 
சை்ப ்தப்பட்டவரக்ை் பாரக்க் கூடுை். 
இ ்த ஆய்விலிரு ்து பின்வாங்கிக் மகாை்ைலாைா? 
  இ ்த ஆய்வில் பங்கு மபறுவது தன்னிசள்சயான முடிவாகுை். இ ்த ஆய்வு 
மதாடங்கிய பிறகுை் இதிலிரு ்து ீ ங்கை் மவைிநயறலாை். அவ்வாறு மசய்வதன் 
மூலை் ந ாயாைிக்கு கிளடக்குை் கவனதத்ிநலா சிகிசள்சயிநலா எ ்த ஒரு 
குளறயுை் இருக்காது. 
 
நைலுை் ச ்நதகங்களுக்கு, மதாடரப்ு மகாை்ைவுை்: 
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ைரு. மெமின் மெ மவப்ஸ்டர,் 
ைருதத்ுவப் பிரிவு  
கிறிஸ்துவ ைருத்துவக் கல்லூரி, நவலூர ்632002, 
இ ்தியா 
மதாளலநபசி: 9894851282 
மின்னஞ்சல்: jemin.webster@cmcvellore.ac.in  
 
ைருதத்ுவைளன 
எண் 
ஆய்வு 
அளடயாை எண் 
மபயர ் வயது 
    
 
 
1) இ ்த ஆய்வு குறிதத் தகவல் விவரங்கை் அளனத்ளதயுை் முழுளையாக 
படித்து ச ்நதகங்களையவை் நகட்டு அறி ்துக் மகாை்ளுை் வாய்ப்பு 
மபற்நறன் என உறுதி அைிக்கிநறன்.(  ) 
2) இ ்த ஆய்வில் என் பங்நகற்பு என் முழுளையான சை்ைத்துடனுை் 
விருப்பத்தின் நபரிலுை் என்பளதயுை்  ான் எப்மபாழுது 
நவண்டுைானாலுை் இ ்த ஆய்விலிரு ்து விலகிக் மகாை்ைலாை் 
என்பளதயுை் அறி ்துை்நைன். (  ) 
3) இ ்த ஆய்ளவ  டதத்ுகின்றவரக்ளுை் அவரக்ைின் சாரப்ாக பணிபுரியுை் 
ஊழியரக்ளுை், ம றிமுளறக் குழுவினருை், ைற்றுை் ஒழுங்குமுளற 
அதிகாரிகளுை், என்னுளடய விவரங்கை் அடங்கிய பதிநவடுகளை 
பாரள்வயிட அளவகளை ளவதத்ுக் மகாை்ை என்னுளடய ஒப்புதல் 
அவசியமில்ளல என்பளதயுை்;  ான் இளடயில் விலகிக் மகாண்டாலுை் 
என் விவரங்களை பாரள்வயிட ளவத்து மகாை்ை நைலுை் ஆய்வில் 
அளவகளை பயன்படுத்த எனக்கு  ஆட்நசபளன இல்ளல என்பளதயுை் 
மதறிவித்துக் மகாை்கிநறன். அளவகைில் என் மபயர ்ைற்றுை் தனிப்பட்ட 
விவரங்கை் மவைியிட படாது என்பளத ான் அறிநவன்.(  ) 
4) அறிவியல் வைரச்ச்ி சார ்்த ந ாக்கங்களுக்காக எனது விவரங்களை 
பயன்படுதத் எ ்தத் தளடயுை் இல்ளல என்பளதயுை்  ான் ஒத்துக் 
மகை்கிநறன். (  ) 
5) இ ்த ஆய்வில்  ான் பங்நகற்க, என் மூளைத் தண்டுவட திரவத்ளத 
பறிநசாதளன மசய்ய, என் சை்ைதத்ளத மதரிவிக்கிநறன். (   ) 
 
ஆய்வில் பங்நகற்பவர,் ளகமயாப்பமிட்டவர ்மபயர_்_______________________ 
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ளகமயாப்பை்/ மபருவிரல் நரளக             ஆராய்சச்ியாைரின் ளகமயாப்பை் 
 
நததி_____________ 
சாட்சச்ியின் மபயர_்__________________________________ 
 
 
ளகமயாப்பை்/ மபருவிரல் நரளக 
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1.13. CRF/PROFORM 
 
Study No:    
 
 
CSF Analysis  Detected Other Sites  Detected 
AFB  Yes  No Sputum AFB   Yes  No 
Culture 
 MGIT 
 LJ 
 
 
 
 
Yes  No 
Extra pulmonary 
 Lymph node 
 Abdominal 
 Genito Urinary 
 
 
Yes  No 
Yes  No 
Yes  No 
Xpert PCR  Yes  No GJ AFB  Yes  No 
 
Name:  Age: Sex:  M     F  
Imaging  
CXR      MRI      CT    
Findings 
 Signs of tuberculosis     
 Miliary tuberculosis         
Definite TBM Criteria Detected 
➢ Mycobacterium tuberculosis Detection 
 Cultured from the CSF 
 CSF positive Xpert 
 AFB positive 
Yes  No 
Ip No        
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Clinical criteria (Max cat score=6) 
➢ Symptom duration of more than 5 days  
 4  
➢ Systemic symptoms suggestive of tuberculosis (one or more of 
the following):  
 Weight loss      
 Night sweats 
 Persistent cough for more than 2 weeks  
 
 
 
 
1 
➢ History of recent (within past year) close contact with an 
individual with PTB   1 
➢ Focal neurological deﬁcit (excluding cranial nerve palsies)   
 1 
➢ Cranial nerve palsy   
 1 
CSF criteria (Max cat score=4) 
➢ Clear appearance  
  1  
➢ Cells: 10–500 per μl   
  1 
➢ Lymphocytic predominance (>50%) 
  1 
➢ Protein concentration greater than 1 g/L   
  1 
➢ CSF to plasma glucose  
 Ratio of less than 50% or  
 An absolute CSF glucose concentration less 
than 40mg/dl 
   
 
 
1 
Cerebral imaging criteria (Max cat score=6) 
➢ Hydrocephalus 
 1  
➢ Basal meningeal enhancement  
 2 
➢ Acid-fast bacilli seen in the context of histological changes consistent with 
tuberculosis in the brain or spinal cord with suggestive symptoms or signs and 
CSF changes, or visible meningitis (on autopsy). 
Yes  No 
118 
 
➢ Tuberculoma 
 2 
➢ Infarct 
 1 
➢ Pre-contrast basal hyper density 
 2 
Evidence of tuberculosis elsewhere (Max cat score=4) 
➢ Chest radiograph suggestive of active tuberculosis: 
 Signs of tuberculosis=2 
 Miliary tuberculosis=4  
 
 
 
2/4 
 
➢ CT/ MRI/ ultrasound evidence for tuberculosis outside the CNS  
 2 
➢ AFB identified /TB cultured from another source                            
 4  
➢ Positive NAAT from extra neural site                                                 
 4  
 Total Score 
 
 
 
HIV status 
Positive           Negative        Not assessed  
 
 
Definite TBM 
 
Probable TBM Score 
>10 without imaging 
>12 with imaging 
Possible TBM Score 
 6-9 without imaging 
 6-11 with imaging 
Not TBM 
 
  
Alternate diagnosis Confirmed by 
 Microbiology             Serology          Histopathology 
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1.14. DATA 
 
 
 
DATA SHEET 
slno sdyno age sex csfafb csfafbr csfmgit csfmgitr csflj
1 1 52 1 1 2 1 2 2
2 2 34 2 1 2 1 2 2
3 3 57 1 2 0 1 2 2
4 4 41 1 1 2 1 2 2
5 5 34 2 1 2 1 2 2
6 6 77 1 2 0 1 2 2
7 10 47 2 2 0 1 2 2
8 12 44 1 1 2 1 1 2
9 15 28 2 2 0 1 2 2
10 16 27 2 2 0 1 2 2
11 17 59 1 2 0 1 2 2
12 18 21 1 2 0 1 2 2
13 19 32 1 1 2 1 1 2
14 20 18 1 1 2 1 2 2
15 21 23 1 1 2 1 2 2
16 22 25 2 1 2 1 1 2
17 23 20 1 1 2 1 1 2
18 24 32 2 2 0 2 0 2
19 25 31 1 1 2 1 2 2
20 26 31 1 2 0 2 0 2
21 27 30 2 1 2 1 2 2
22 28 25 2 1 2 1 1 2
23 29 47 2 1 2 1 1 2
24 30 42 2 1 2 1 1 2
25 31 64 2 1 2 1 2 2
26 32 25 2 1 2 1 1 2
27 33 18 1 1 1 1 1 2
28 34 56 1 1 2 1 2 2
29 35 46 1 1 2 1 2 2
30 36 55 2 1 2 1 2 2
31 37 25 1 1 2 1 2 2
32 38 57 1 1 2 1 2 2
33 39 27 1 1 2 1 2 2
34 40 23 1 2 0 2 0 2
35 41 52 1 1 2 1 2 2
36 42 41 1 1 2 1 2 2
37 43 42 1 1 2 1 2 2
38 44 1 1 1 2 1 2 2
39 45 62 1 1 2 1 2 2
40 46 46 2 1 2 1 2 2
41 47 32 1 1 2 1 2 2
42 48 27 1 1 2 1 2 2
43 49 38 1 1 2 1 2 2
120
csfljr csfxpt csfxptr spuafb spuafbr gjafb gjafbr lnafb lnafbr
0 1 2 2 2 2 0 2 0
0 1 1 2 2 2 0 2 0
0 2 0 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 2 0 1 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 2 0 2 2 0 2 0
0 1 2 2 2 0 2 0
0 2 0 2 2 0 2 0
0 1 1 2 2 0 2 0
0 1 2 2 2 0 2 0
0 2 0 2 2 0 2 0
0 2 0 2 2 0 2 0
0 2 0 2 2 0 2 0
0 2 0 2 2 0 2 0
0 1 1 2 2 0 2 0
0 1 1 2 2 0 2 0
0 1 2 2 2 0 2 0
0 2 0 2 2 0 2 0
0 2 0 1 2 2 0 2 0
0 1 1 2 2 0 2 0
0 1 2 2 2 0 2 0
0 2 0 2 2 0 2 0
0 1 2 2 2 0 2 0
0 2 0 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 2 0 2 2 0 2 0
0 1 2 2 2 0 2 0
0 2 0 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
121
ctbrtb mrbrtb cxrtb othima ctthora ctadom deftbm csfznr1 csfmgt1
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 1 2 2
2 2 2 2 0 0 2 0 2
2 2 2 2 0 0 2 2 2
2 1 2 2 0 0 2 2 2
2 2 1 2 0 0 2 0 2
2 2 2 2 0 0 2 0 2
2 2 2 2 0 0 1 2 1
1 1 2 2 0 0 2 0 2
2 2 2 1 2 0 2 0
1 1 2 2 0 0 2 0 2
1 1 2 2 0 0 2 0 2
1 1 2 2 0 0 1 2 1
2 2 2 2 0 0 2 2 2
0 0 0 2 0 0 2 2 2
1 1 2 2 0 0 1 2 1
2 1 2 2 0 0 1 2 1
0 0 0 2 0 0 2 0 0
1 1 2 2 0 0 2 2 2
1 1 2 2 0 0 2 0 0
2 2 2 2 0 0 2 2 2
1 1 2 2 0 0 1 2 1
1 1 2 2 0 0 1 2 1
1 1 2 2 0 0 1 2 1
0 0 0 2 0 0 2 2 2
2 1 2 2 0 0 1 2 1
1 2 2 2 0 0 1 1 1
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 1 2 2 0 0 2 2 2
2 2 2 2 0 0 2 0 0
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 1 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 1 2 2 0 0 2 2 2
122
csfxpt1 csfljr1 afbhis1 clincri syp5days symsugtb focndef cranerpa altconcs
2 0 0 6 4 1 0 1 1
1 0 0 5 4 1 0 0 0
0 0 0 6 4 1 0 1 1
2 0 2 5 4 1 0 0 0
2 0 0 5 4 1 0 0 0
0 0 0 0 0 0 0 0 0
2 0 0 0 0 0 0 0 0
2 0 0 6 4 1 1 0 0
2 0 0 6 4 1 1 0 1
0 6 4 0 0 1 1
2 0 0 4 4 0 0 0 0
2 0 0 5 4 1 0 0 0
0 0 0 6 4 1 0 0 1
2 0 0 5 4 1 0 0 0
2 0 0 5 4 1 0 0 0
1 0 0 5 4 1 0 0 0
2 0 0 6 4 1 0 0 1
0 0 0 0 0 0 0 0 0
0 0 0 5 4 1 0 0 0
0 0 0 6 4 1 0 0 1
0 0 0 4 4 0 0 0 0
1 0 0 5 4 1 0 0 0
1 0 0 5 4 1 0 0 0
2 0 0 5 4 1 0 0 0
0 0 0 5 4 1 0 0 0
0 0 0 6 4 1 1 1 0
1 0 0 5 4 0 1 0 0
2 0 0 6 4 1 0 1 0
0 0 0 5 4 1 0 0 0
2 0 0 0 0 0 0 0 0
0 0 0 5 4 1 0 0 0
2 0 0 4 4 0 0 0 0
2 0 0 0 4 1 0 0 0
0 0 0 0 0 0 0 0 0
2 0 0 5 4 1 0 0 0
0 0 0 6 4 1 1 0 0
2 0 0 5 4 1 0 0 0
2 0 0 5 4 0 1 0 0
2 0 0 5 4 1 0 0 0
2 0 0 0 0 0 0 0 0
2 0 0 0 0 0 0 0 0
2 0 0 4 4 0 0 0 0
2 0 0 6 4 1 1 0 0
123
clincrt csfcrit clearapp counts lymppre proconc csfplglu csfglu40 csfgluc
4 1 1 0 1 1 1 1
3 1 1 0 1 0 0 0
3 1 0 0 1 1 1 1
4 1 1 1 0 1 1 1
4 1 1 1 0 1 1 1
4 1 1 1 1 1 1 1
4 1 1 1 1 1 1 1
4 1 1 0 1 1 1 1
3 1 1 1 0 0 0 0
4 1 1 1 1 1 1 1
4 1 1 1 1 1 1 1
3 1 1 1 0 0 0 0
4 1 1 1 1 1 1 1
4 1 1 1 1 1 1 1
3 1 1 1 0 0 0 0
4 1 1 1 1 1 1 1
4 1 1 0 1 1 1 1
4 1 1 1 1 0 0 0
4 1 1 1 1 1 1 1
4 1 1 1 1 0 0 0
3 1 1 1 0 0 0 0
4 1 1 1 1 1 1 1
3 1 1 1 0 0 0 0
4 1 1 1 1 0 0 0
4 1 1 1 1 0 0 0
4 1 1 1 1 1 1 1
2 1 1 0 0 0 0 0
4 1 1 1 1 0 0 0
1 1 0 0 0 0 0 0
4 1 1 1 1 0 0 0
1 0 0 0 1 0 0 0
3 1 1 0 1 0 0 0
4 1 1 0 1 1 1 1
2 1 1 0 0 0 0 0
4 1 1 1 1 1 1 1
1 1 0 0 0 0 0 0
4 1 1 1 1 0 0 0
4 1 1 1 1 0 0 0
4 1 1 1 1 1 1 1
2 1 1 0 0 0 0 0
4 1 1 1 1 1 1 1
4 1 1 1 1 1 1 1
4 1 1 1 1 0 0 0
124
csfcrt csfimacr hycep basmenen tuloma infarct prconhyd csfimct evtbels
6 1 2 0 1 2 0
4 0 2 2 0 0 4
6 1 2 2 1 2 0
0 0 0 0 0 0 0
4 0 2 0 0 2 4
0 0 0 0 0 0 4
0 0 0 0 0 0 0
0 0 0 0 0 0 4
3 1 2 0 0 0 0
0 0 0 0 0 0 0
4 0 2 2 0 0 0
3 1 2 0 0 0 0
6 1 2 2 0 2 0
2 0 0 0 0 2 0
0 0 0 0 0 0 0
3 1 2 0 0 0 0
3 0 2 0 1 0 4
0 0 0 0 0 0 0
4 0 2 2 0 0 0
6 1 2 2 0 2 4
0 0 0 0 0 0 0
3 1 2 0 0 0 0
2 0 0 2 0 0 0
2 0 0 2 0 0 4
0 0 0 0 0 0 4
4 2 0 0 0 0 2 0
6 1 2 0 1 2 0
2 0 0 2 0 0 4
0 0 0 0 0 0 4
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
6 0 2 2 0 2 4
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
2 0 0 0 0 2 2
0 0 0 0 0 0 0
5 1 2 0 0 2 0
0 0 0 0 0 0 0
2 0 0 0 0 2 0
2 0 0 2 0 0 0
6 1 2 2 1 0 0
125
sigtb miltb othimtb afbidel naat evtbelt toscore toscorei hivsta
0 0 0 0 0 10 16 2
0 4 0 0 0 12 16 2
0 0 0 0 0 9 15 2
0 0 0 0 0 0 10 10 1
0 0 0 0 4 13 17 1
0 0 0 4 0 8 8 2
0 0 0 0 0 4 4 2
0 0 0 4 0 14 14 2
0 0 0 0 0 9 12 2
0 0 0 0 0 10 10 2
0 0 0 0 0 8 12 2
0 0 0 0 0 8 11 2
0 0 0 0 0 10 16 2
0 0 0 0 0 9 11 2
0 0 0 0 0 8 8 2
0 0 0 0 0 9 12 2
0 0 0 4 4 14 17 2
0 0 0 0 0 4 4 2
0 0 0 0 0 9 13 2
0 0 0 4 0 14 20 2
0 0 0 0 0 7 7 2
0 0 0 0 0 9 12 2
0 0 0 0 0 8 10 1
0 4 0 0 0 13 15 2
0 4 0 0 0 13 13 2
0 0 0 0 0 10 12 2
0 0 0 0 0 7 13 2
0 0 0 4 0 14 16 2
0 0 0 4 0 10 10 2
0 0 0 0 0 4 4 1
0 0 0 0 0 6 6 2
0 0 0 0 0 7 7 2
0 0 0 4 0 8 14 2
0 0 0 0 0 2 2 2
0 0 0 0 0 9 9 1
0 0 0 0 0 7 7 2
0 0 2 0 0 11 13 2
0 0 0 0 0 9 9 2
0 0 0 0 0 9 14 2
0 0 0 0 0 2 2 2
0 0 0 0 0 4 6 2
0 0 0 0 0 8 10 2
0 0 0 0 0 10 16 2
126
altdia altdiby landiag mznrest csfceln csfcelp csfcell csfcelm csfgluc1
2 2 2 300 1 99 0 28
2 1 2 160 60 36 4 47
2 1 2 2 10 6 88 5 75
1 1 4 2 15 10 90 0 5
2 2 2 12 4 96 0 39
2 4 2 12 8 86 6 104
2 4 2 120 30 63 7 35
2 1 2 130 60 24 16 18
2 2 2 30 9 91 0 65
2 3 2 150 64 34 2 34
2 2 2 120 15 85 0 40
2 3 2 130 18 74 8 52
2 1 1 85 23 77 0 59
2 3 2 60 3 92 4 64
2 3 2 44 2 83 15 60
2 1 2 124 37 58 0 12
2 1 2 250 78 20 2 57
2 4 2 150 21 76 3 47
2 2 2 20 1 97 2 24
2 2 2 85 23 77 0 59
1 2 4 2 400 8 76 16 65
2 1 2 200 69 30 1 19
2 1 2 90 0 85 6 50
2 1 2 140 7 81 12 51
2 2 2 820 48 52 0 89
2 1 2 810 36 58 6 21
2 1 1 20 93 2 5 70
1 2 4 2 19 2 90 8 51
2 3 2 4 10 90 0 90
1 2 4 2 120 9 86 3 47
2 4 2 700 1 96 3 46
2 3 2 9 36 64 0 65
2 2 2 240 61 38 0 48
2 4 2 110 2 93 4 118
2 3 2 90 24 75 0 34
2 3 2 1 0 0 0 71
2 2 2 3 12 88 0 35
2 3 2 220 2 98 0 61
2 2 2 180 10 87 0 33
2 4 2 360 93 7 0 124
1 1 4 2 80 16 81 2 5
2 3 2 150 18 74 8 64
2 2 2 60 1 98 1 42
127
csfprot mrc gcs altdian
218 1 15
389 1 15
259 3
98 15 Cryptococcal Meningi
55 1 15
168 2 12
117 15
117 1 15
671 1 15
357
192 1 15
87 2 15
136 2 10
147 3 15
45 1 15
337 1 15
116 3 13
68 2 15
391 2 15
136 2 10
130 15 Scrub Typhus
564 1 15
95 2 15
273 2 14
211 1 15
190 3 15
33 3 6
100 3 8 Toxoplasmosis
63 1 15
542 8
119 1 15
199 1 15
293 1 15
67 15 Aseptic meningitis
336 1 15
84 1 15
404 2 13
198 1 15
289 1 15
87 9
356 15 Cryptooccal meningit
62 1 15
119 3 7
128
44 50 35 1 2 0 2 0 2
45 51 24 1 1 2 1 2 2
46 52 57 1 1 2 1 2 2
47 55 33 1 1 2 1 3 2
48 57 22 1 1 2 1 2 2
49 58 35 2 1 2 1 3 2
50 59 35 1 1 2 1 3 2
51 60 61 1 1 1 1 3 2
52 61 32 2 1 2 1 3 2
53 62 24 1 2 0 2 0 2
54 63 66 1 1 2 1 2 2
55 64 47 1 1 2 1 2 2
56 66 72 1 1 2 1 3 2
57 67 30 2 1 2 1 3 2
58 68 48 1 1 2 1 3 2
59 69 59 1 2 0 2 0 2
60 70 34 1 1 2 1 3 2
61 71 72 1 1 2 1 3 2
62 72 63 1 1 2 1 3 2
63 73 26 1 1 2 1 3 2
64 74 25 1 1 2 1 1 2
65 75 57 1 1 2 1 2 2
66 76 44 1 1 2 1 1 2
67 77 28 1 1 2 1 2 2
68 78 62 1 1 2 1 1 2
69 79 49 2 1 2 1 2 2
70 80 37 2 1 2 1 2 2
71 81 23 1 1 2 1 2 2
72 7 60 1 1 2 1 2 2
73 8 53 1 2 0 2 0 2
74 9 34 2 1 2 1 2 2
75 11 47 1 1 1 1 1 2
76 13 33 1 1 2 1 2 2
77 14 28 1 1 2 1 2 2
78 53 24 1 1 2 1 2 2
79 54 29 1 1 2 1 2 2
80 56 43 1 1 2 1 3 2
81 65 43 1 2 0 2 0 2
129
0 2 0 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 2 0 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 1 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 2 0 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 2 0 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 2 0 2 2 0 2 0
0 2 0 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 1 2 2 0 2 0
0 2 0 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 2 0 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 2 0 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 1 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
0 1 2 2 2 0 2 0
130
2 2 2 2 0 0 2 0 0
2 2 2 2 0 0 2 2 2
2 1 2 2 0 0 2 2 2
2 2 2 2 0 0 3 2 3
2 2 2 2 0 0 2 2 2
2 1 2 2 0 0 2 2 3
2 2 2 2 0 0 1 2 3
2 2 2 2 0 0 1 1 3
2 1 2 2 0 0 2 2 3
2 2 2 2 0 0 2 0 0
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 3
2 2 2 2 0 0 2 2 3
2 2 2 2 0 0 2 2 3
2 2 2 2 0 0 2 0 0
2 2 2 2 0 0 2 2 3
2 2 2 2 0 0 2 2 3
2 2 2 2 0 0 2 2 3
2 2 2 2 0 0 2 2 3
2 2 2 2 0 0 1 2 1
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 1 2 1
2 2 2 2 0 0 2 2 2
2 1 2 2 0 0 1 2 1
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 0 0
2 2 2 2 0 0 2 2 2
2 2 1 2 0 0 1 1 1
2 1 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 2
2 2 2 2 0 0 2 2 3
2 2 2 2 0 0 2 0 0
131
0 0 0 4 4 0 0 0 0
2 0 0 5 4 1 0 0 0
2 0 0 5 4 1 0 0 0
0 0 0 0 0 0 0 0 0
2 0 0 5 4 1 0 0 0
2 0 0 4 4 0 0 0 0
1 0 0 5 4 1 0 0 0
2 0 0 5 4 1 0 0 0
2 0 0 4 4 0 0 0 0
2 0 0 2 0 0 0 1 1
0 0 0 0 0 0 0 0 0
2 0 0 0 0 0 0 0 0
2 0 0 5 4 0 0 1 0
2 0 0 6 4 1 0 0 1
2 0 0 6 4 1 1 0 1
0 0 0 5 4 0 0 1 0
2 0 0 6 4 0 1 0 1
2 0 0 6 4 0 1 0 1
0 0 0 5 4 0 0 0 1
0 0 0 6 4 1 1 0 1
2 0 0 6 4 1 1 0 1
2 0 0 6 4 1 0 1 1
1 0 0 5 4 1 0 0 0
0 0 0 4 4 0 0 0 0
2 0 0 4 4 0 0 0 0
2 0 0 4 4 0 0 0 0
0 0 0 4 4 0 0 0 0
2 0 0 4 4 0 0 0 0
2 0 0 4 4 0 0 0 0
0 0 0 5 4 0 0 0 1
2 0 0 5 4 1 0 0 0
1 0 0 6 4 1 0 0 1
2 0 0 6 4 1 0 1 0
2 0 0 6 4 1 0 0 1
2 0 0 1 0 0 0 0 1
2 0 0 4 4 0 0 0 0
2 0 0 4 4 0 0 0 0
2 0 0 5 4 1 0 0 0
132
3 1 1 1 0 0 0 0
3 1 1 1 0 0 0 0
4 1 1 1 1 1 1 1
3 1 1 1 0 0 0 0
4 1 1 1 1 1 1 1
4 1 1 1 1 0 0 0
4 1 1 1 1 1 1 1
4 1 1 1 1 1 1 1
3 1 1 1 0 0 0 0
3 1 1 1 0 0 0 0
3 1 1 0 1 0 0 0
3 1 1 1 0 0 0 0
4 1 1 1 1 0 0 0
4 1 1 1 1 0 0 0
4 1 1 0 1 1 1 0
1 1 0 0 0 0 0 0
4 1 1 1 1 1 1 1
4 1 1 1 1 1 0 0
4 1 1 1 1 0 0 0
4 1 1 1 1 0 0 0
4 1 1 1 1 1 1 1
4 1 1 1 1 1 1 1
4 1 1 1 1 1 1 1
4 1 1 1 1 1 1 1
4 1 1 1 1 1 1 1
3 1 1 0 1 0 0 0
3 1 1 1 0 0 0 0
4 1 1 1 1 0 0 0
4 1 1 1 1 1 1 1
4 1 1 1 1 1 1 1
4 1 1 1 1 0 0 0
4 1 1 1 1 1 1 1
4 1 1 1 1 0 0 0
3 1 1 1 0 0 0 0
4 1 1 0 1 1 1 1
4 1 1 1 1 1 1 1
3 1 1 1 0 0 0 0
4 1 1 1 1 0 0 0
133
0 0 0 0 0 0 0
0 0 0 0 0 0 0
5 1 2 0 0 2 2
0 0 0 0 0 0 0
0 0 0 0 0 0 4
4 0 2 0 0 2 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
4 0 2 2 0 0 0
2 0 0 0 0 2 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
6 1 2 0 1 2 2
2 0 2 0 0 0 0
5 0 2 0 1 2 2
1 0 0 0 1 0 0
4 0 2 0 0 2 0
5 0 2 0 1 2 2
0 0 0 0 0 0 0
6 1 2 0 1 2 2
4 0 2 2 0 0 0
4 0 2 2 0 0 2
3 1 2 0 0 0 2
0 0 0 0 0 0 4
4 1 2 0 1 0 4
0 0 0 0 0 0 0
2 0 2 0 0 0 0
4 0 2 0 0 2 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
4 0 2 2 0 0 4
0 0 0 0 0 0 4
1 0 0 0 1 0 4
6 1 2 0 1 2 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
3 0 2 0 1 0 0
134
0 0 0 0 0 7 7 2
0 0 0 0 0 8 8 2
2 0 0 0 0 11 16 1
0 0 0 0 0 3 3 2
2 0 2 0 0 13 13 2
0 0 0 0 0 8 12 2
0 0 0 0 0 9 9 1
0 0 0 0 0 9 9 2
0 0 0 0 0 7 11 2
0 0 0 0 0 5 7 2
0 0 0 0 0 3 3 2
0 0 0 0 0 3 3 2
2 0 0 0 0 11 17 2
0 0 0 0 0 10 12 1
0 0 2 0 0 12 17 2
0 0 0 0 0 6 7 2
0 0 0 0 0 10 14 2
2 0 0 0 0 12 17 2
0 0 0 0 0 9 9 2
0 0 2 0 0 12 18 2
0 0 0 0 0 10 14 2
0 0 2 0 0 12 16 2
0 0 2 0 0 11 14 1
0 4 0 0 0 12 12 2
0 4 0 0 0 12 16 2
0 0 0 0 0 7 7 2
0 0 0 0 0 7 9 2
0 0 0 0 0 8 12 2
0 0 0 0 0 8 8 2
0 0 0 0 0 9 9 2
0 4 0 0 0 13 17 2
0 4 0 0 0 14 14 2
0 0 2 4 4 14 15 2
0 0 0 0 0 9 15 2
0 0 0 0 0 5 5 2
0 0 0 0 0 8 8 2
0 0 0 0 0 7 7 2
0 0 0 0 0 9 12 2
135
2 3 2 80 3 90 0 66
2 3 2 100 12 81 7 24
2 2 2 240 3 97 0 24
2 4 2 260 6 88 5 92
2 2 2 130 22 66 12 21
1 2 4 2 45 10 87 3 54
2 1 2 420 8 92 0 98
2 1 2 350 43 55 2 13
2 3 2 820 9 87 4 73
2 3 2 80 3 97 0 49
2 4 2 150 53 46 1 89
2 4 2 60 10 85 3 149
2 2 2 190 6 81 13 83
2 2 2 110 2 98 0 60
2 2 2 280 70 28 2 38
1 3 4 2 240 73 23 4 87
2 2 2 80 40 58 2 36
2 2 2 250 15 85 0 105
2 3 2 920 8 92 0 47
2 2 2 268 6 87 7 45
2 1 2 128 18 76 6 46
2 2 2 150 4 92 4 71
2 1 2 320 1 99 0 40
2 2 2 190 12 88 0 35
2 1 2 20 10 85 5 49
2 3 2 180 84 11 5 64
2 3 2 15 2 92 6 91
2 2 2 300 6 90 4 71
1 2 4 2 50 1 74 20 73
1 1 4 2 260 31 68 0 10
2 2 2 330 3 94 3 47
2 1 1 140 10 86 4 112
2 2 2 320 12 88 0 56
2 2 2 180 2 92 6 65
1 1 4 2 3480 90 4 6 5
2 3 2 150 17 83 0 26
2 3 2 60 1 96 3 79
2 2 2 590 10 88 2 57
136
48
90 1 15
1100 1 15
66 15
160 1 15
98 15 EBV positive
175 1 15
243 1 15
41 1 15
122 15
101 15
74 7
851 3 10
138 15
105 2 14
56 15 Invasive mucor
147 15
335 3 10
183 3 12
146 3 9
153 2 15
135 2 13
291 1 15
139 2 13
56 1 15
127 15
38
56 1 15
104 15 Scrub typhus
350 14 Strep Pneumonia
168 1 15
339 3 11
399 1 15
94 2 13
455 5 Strep Pneumonia Meni
239
99
365
137
